Stockwinners Market Radar for March 14, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:05 EDT Biogen, Eisai amend collaboration pacts on Alzheimer's treatments - Biogen Inc. and Eisai Co., Ltd. announced that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM. Effective as of January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM rather than sharing global profits and losses. The royalty rate starts at 2% and reaches 8% when annual sales exceed $1B. Effective immediately, Biogen's existing final decision-making rights on ADUHELM have converted to sole decision making and commercialization rights worldwide. Overall, economic arrangements for both companies in 2022 are expected to remain materially unchanged with Eisai's share of expenses capped at an agreed amount for the costs related to development, commercialization, and manufacturing of ADUHELM for the period from January 1, 2022 to December 31, 2022. Once the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM's economics beyond these royalties. The companies will continue to jointly develop and commercialize the investigational therapy lecanemab. Eisai continues to serve as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. Both companies share economics equally with Eisai booking all sales for lecanemab and Biogen reflecting its 50% share of profits and losses. The supply agreement related to lecanemab has been extended from five to 10 years. Biogen will manufacture the lecanemab drug substance in its Solothurn, Switzerland facility with the goal of providing reliable commercial supply worldwide.

18:43 EDT AT&T sees $2.5B in cumulative cost savings over next two years - The company states: "Pascal Desroches, CFO of AT&T Inc., spoke today at the Deutsche Bank Media, Internet & Telecom Conference where he provided an update to shareholders. Desroches reiterated AT&T's growth strategy - introduced at the company's Analyst & Investor Day on March 11 - for the standalone company following the pending close of the WarnerMedia transaction. AT&T intends to become America's best broadband provider, underpinned by a best-in-class network with fiber at its foundation and integrated with wireless. AT&T has announced that it expects to: 1) Drive additional wireless subscriber growth by maintaining its consistent go-to-market strategy, increasing penetration in underserved customer segments and cross-selling wireless services into its expanding fiber footprint. 2) Continue to optimize its cost structure via ongoing transformation initiatives, with opportunities to drive an additional $2.5 billion in cumulative cost savings over the next 2 years to reach its previously announced goal of $6 billion in run-rate cost savings by the end of 2023. 3) Maintain a total-return oriented capital allocation strategy with a focus on investing for growth - with capital investment in the $24 billion range for 2022 and 2023 - and strengthening its balance sheet."

18:23 EDT Dutch Bros CEO: We're very disciplined about our expansion plans - In an interview on CNBC's Mad Money, Joth Ricci said Dutch Bros just celebrated its 30-year anniversary. The business was built on the back of an amazing culture and has expanded very carefully, he added. It intends to stay very disciplined about expansion, he noted. "We're well suited for financing growth well into the future and we're in a good spot," he said. "We feel good about our recipe for growth."

17:45 EDT Google Cloud updates infrastructure capabilities and pricing - Sachin Gupta, Vice President and GM, Google Cloud Infrastructure said partly, in an earlier blog posting: "Over the past several years, Google Cloud has made significant investments in our infrastructure product portfolio. We launched new Tau T2D VMs, which deliver 42% better price-performance vs. other leading cloud providers. We upgraded Cloud Storage to offer more flexibility to support customers' enterprise and analytics workloads, with dual-region buckets and upcoming Turbo Replication. And we've delivered numerous improvements to our global network, including expansion to 29 cloud regions. However, from conversations with customers, we've also learned we can do more to align our capabilities and pricing with their varied workloads. So, today, we are announcing we will adjust our infrastructure product and pricing structure to give customers more choice in how they pay for what they use alongside new, flexible SKUs with new product options and capabilities...Today, we sent customers a six-month notice on the price changes, which go into effect on October 1, 2022. Customers under existing commit contracts with a floating or fixed discount will not face any changes until renewal. Some of these changes will provide new, lower-cost options and features for Google Cloud products. Other changes will raise prices on certain products." Reference Link

17:17 EDT ArrowMark Financial Corp. reports estimated NAV $21.75 as of February 28 - ArrowMark Financial Corp. announced that the company's estimated and unaudited Net Asset Value as of February 28 was $21.75. The NAV was up 1c from the prior month.

17:01 EDT Loyalty Ventures takes steps to 'pause business in Russia' - Loyalty Ventures provided an update on its operations in Russia. The company has taken steps to pause business in Russia, but will honor its commitments to current programs with Russian grocery chain clients in fulfillment of contractual obligations. However, the company does not plan to offer new loyalty campaigns there for the time being. The vast majority of products the company uses for its campaign-based loyalty solutions in Russian grocery stores are sourced internationally, and none of the rewards for loyalty campaigns outside of Russia are sourced from Russian suppliers. For full year 2022, the company projects that its decision to pause its loyalty campaigns for Russian grocery chains will result in lost revenues of approximately $16M. For the year ended December 31, 2021, Loyalty Ventures' revenue was $735M.

16:50 EDT AnaptysBio trading resumes

16:43 EDT Chipotle officer Marissa Andrada sells $2.2M in company shares - Chipotle officer Marissa Andrada disclosed in a regulatory filing that she had sold 1,456 shares of company stock at $1,480.76 per share for a total transaction amount of $2,155,990.

16:34 EDT Huntington Ingalls delivers Virginia-class submarine to U.S. Navy - HI announces that "on Friday, (it has) delivered the newest Virginia-class fast-attack submarine to the U.S. Navy. Montana (SSN 794), which successfully completed sea trials last month, is the 10th Virginia-class submarine to be delivered by HII's Newport News Shipbuilding division and the 21st built as part of the teaming agreement with General Dynamics' Electric Boat."

16:32 EDT Vimeo reports monthly YoY February revenue growth 23% vs. 54% last year - Reports February YoY subscriber growth 8% versus 26% last year; Reports February YoY average revenue per user or ARPU up 13% vs. 27% last year.

16:29 EDT Clover Health appoints Joseph Martin as general counsel - Clover Health announced the appointment of Joseph Martin as general counsel, effective March 14. Martin will serve on Clover's management team and will report to Vivek Garipalli, CEO of Clover. Before joining Clover, Martin served as general counsel for Steel Partners Holdings

16:26 EDT Paylocity promotes Toby Williams to co-CEO, Ryan Glenn to CFO - Paylocity announced the promotion of Toby Williams to president and co-CEO, and Ryan Glenn to CFO effective immediately. Steve Beauchamp, who joined Paylocity in 2007, will continue to serve as co-CEO and a member of the board of directors. As president and co-CEO, Williams, who joined Paylocity in 2017 as CFO, will also join Paylocity's board of directors. "Toby is an extremely talented executive who has helped scale and grow our business over the last 4+ years, and I'm very excited for him to join me as Co-CEO as we continue to focus on growing Paylocity by providing world-class service and industry-leading technology to our clients," said Beauchamp.

16:24 EDT SuRo Capital boosts amount of share repurchase pact by $15M to $55M - SuRo Capita announced its Board of Directors has increased the amount of common shares that may be repurchased under the Share Repurchase Program by $15M to $55M aggregate. "As we have consistently demonstrated, SuRo Capital is committed to initiatives that enhance shareholder value and we believe the market is currently undervaluing our portfolio. Accordingly, our Board of Directors has authorized an additional $15M for share repurchases, bringing our Share Repurchase Program total to $55M. Given the significant discount at which our stock is trading compared to net asset value, coupled with the extreme market volatility, we determined that this authorization is an efficient and accretive deployment of capital," said Mark Klein, Chairman and Chief Executive Officer of SuRo Capital. On March 13 the Company's Board of Directors authorized a $15M expansion of the Share Repurchase Program to $55M. The dollar value of shares that may yet be purchased by the Company under the Share Repurchase Program is approximately $25M. The Share Repurchase Program is authorized through October 31.

16:23 EDT MediaAlpha announces $5M share repurchase program - MediaAlpha announced that its Board of Directors has approved a share repurchase program that authorizes the company to purchase up to $5M of the Company's Class A common stock from time to time in open market transactions at prevailing prices or by other means in accordance with federal securities laws. The repurchases are expected to be made over the second and third quarters of 2022.

16:22 EDT Northwest Pipe selected for Navajo-Gallup water supply project - Northwest Pipe "has been selected by S.J. Louis Construction, Inc., a Minnesota-based general contractor specializing in underground utility construction for 39 years, to manufacture engineered steel water transmission pipe for the Code Talkers Lateral Reaches 12.1 and 12.2 of the Navajo-Gallup Water Supply Project. Northwest Pipe Company is manufacturing over 1,813 tons of 24-inch and 30-inch diameter engineered steel pipeline. Some of pipe will have epoxy lining with a paint coating while other segments will have cement mortar lining and polyurethane coating. The Company is manufacturing the pipe at the San Luis Rio Colorado in Sonora, Mexico facility. The Company also recently supplied pipeline for the project on Reaches 4C through 8."

16:19 EDT EcoR1 Capital reports 9.9% passive stake in Surface Oncology - Oleg Nodelman's EcoR1 Capital disclosed a 9.9% stake in Surface Oncology, which represents over 4.65M shares. The filing with the SEC is for a passive stake and does not allow for activism.

16:18 EDT CarLotz launches mobile application - CarLotz announced that it has launched a mobile application. The app is available for Android and iOS devices in the App Store and Google Play.

16:18 EDT FB Financial announces $100M stock buyback - FB Financial announced that its Board of Directors has authorized and empowered a special committee of the Board of Directors to commence a stock repurchase program of up to $100 million of the Company's outstanding common stock. The repurchase authorization will be in place until January 31, 2024, and replaces the Company's previous authorization, which expires on March 31, 2022.

16:17 EDT Qurate Retail names Terry Boyle as President & CEO of Zulily - Qurate Retail President and CEO David L. Rawlinson II announced the appointment of Terry Boyle as President & CEO of Zulily effective March 14. Boyle will report to and work in collaboration with Rawlinson to develop and implement a compelling strategy for Zulily to optimize short- and long-term business goals.

16:16 EDT Texas Pacific Land announces $100M stock buyback - Texas Pacific Land Corporation announced that the company's board of directors approved a stock repurchase program to purchase up to an aggregate of $100M of its outstanding common stock. Acquisitions pursuant to the stock repurchase program may be made through a combination of open market repurchases in compliance with Rule 10b-18 promulgated under the Securities Exchange Act of 1934, as amended, privately negotiated transactions, and/or other transactions at the company's discretion. In connection with the stock repurchase program, the company intends to enter into a Rule 10b5-1 trading plan that would generally permit the company to repurchase shares at times when it might otherwise be prevented from doing so under securities laws. The stock repurchase program will expire on December 31, 2022 unless otherwise modified or earlier terminated by our board of directors at any time in its sole discretion.

16:15 EDT Tilly's board authorizes repurchase of up to 2M class A shares - Tilly's announced that its Board of Directors has authorized a share repurchase program, pursuant to which the Company may repurchase up to two million shares of the Company's Class A common stock over the next twelve months through March 14, 2023. Repurchases of Class A common stock by the Company pursuant to the Program may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or by other means in accordance with federal securities laws, including pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Exchange Act. The Company is not obligated to repurchase any specific number or amount of shares of Class A common stock pursuant to the Program, and it may modify, suspend or discontinue the Program at any time. The Company will determine the timing and amount of repurchased shares, if any, in its discretion based on a variety of factors, such as the market price of Class A common stock, corporate requirements, general market economic conditions and applicable legal requirements.

16:12 EDT Circor files Form 12b-25 with SEC - Circor announced that it has filed a Form 12b-25 with the U.S. Securities and Exchange Commission providing the company a 15-day extension to file its Annual Report on Form 10-K (for the year ended December 31, 2021. In the course of completing the audit of the consolidated financial statements to be filed as part of Form 10-K, the Company and the Company's independent registered public accounting firm Ernst & Young LLP uncovered accounting irregularities in the financial statements with respect to the Company's Pipeline Engineering business unit, which is a part of its Industrial reportable segment. The operations for this business unit are primarily located in Catterick, England. Prior to the discovery of these irregularities, the Pipeline Engineering business unit accounted for approximately 3% and 2% of the Company's total reported revenue in 2020 and 2019, respectively. The irregularities, however, preliminarily appear to account for balance sheet and income statement entries in the range of $35 to $45 million of pre-tax income on a cumulative basis over a period of at least five years. These estimates are subject to change until the filing of our Form 10-K and are not inclusive of other direct and indirect accounting effects of the accounting irregularities. The Company, together with an outside law firm and an independent forensic accounting firm, under the oversight of the Audit Committee of the Company's Board of Directors is conducting a review of the financial statements of this business unit. Although the review is still underway, the Company expects to restate its consolidated financial statements for 2019 through 2021. As such, investors should not rely on the Company's previously filed financial statements and related disclosures for the years ended December 31, 2018, December 31, 2019 and December 31, 2020 included in its Annual Reports on Form 10-K, each of the quarterly and year-to-date periods for 2020 and the quarterly and year-to-date periods for the nine months ended October 3, 2021.

16:10 EDT Heritage Global names Raspina Jannesar CMO - Heritage Global announced that Raspina Jannesar has joined its Executive Leadership team as Chief Marketing Officer. As CMO, Jannesar will lead all corporate marketing and branding efforts, including strategy and awareness, tactics and planning, public relations activity, and corporate communications. "We are extremely excited to welcome Raspina to the Heritage Global team," said Ross Dove, CEO. "We have built a profitable and successful company which holds a unique position in the market. We are poised for explosive growth and need to drive awareness of our company, especially to the investor community. We are pleased to have Raspina on board to help with this endeavor."

16:09 EDT Exelixis does not intend to submit supplemental NDA to FDA for cabometyx - Exelixis announced results from the final analysis of the second primary endpoint of overall survival from the phase 3 COSMIC-312 trial, which evaluated cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. The final analysis showed neither improvement nor detriment in OS for cabozantinib in combination with atezolizumab versus sorafenib. Based on this outcome for OS and the rapidly evolving treatment landscape for previously untreated advanced HCC, Exelixis does not intend to submit a supplemental New Drug Application to the U.S. Food and Drug Administration. Full results will be presented at a future medical meeting. "Exelixis has a longstanding commitment to patients with liver cancer, exemplified by the 2019 approval of CABOMETYX for previously treated advanced liver cancer, and we remain steadfast in our journey to further therapies for this and other difficult-to-treat cancers," said Vicki L. Goodman, M.D., Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer, Exelixis. "We are grateful to the investigators and patients who participated in the COSMIC-312 trial and contributed greatly to this research."

16:09 EDT Calavo Growers says seeing sequential improvement in profitability - The company said, "Demand for fresh, healthy and convenient products remains strong even as industry-wide inflationary pressures on raw materials, freight, packaging and labor costs persist. We have and will continue to implement pricing and operational initiatives to offset these items, and we are seeing quarter to quarter sequential improvement in profitability. We are optimistic that we will see ongoing profit improvement from our efforts."

16:03 EDT Wingstop CEO Charlie Morrison resigns, Michael Skipworth to succeed - Wingstop announced the resignation of its Chairman and CEO Charlie Morrison and the appointment of President and COO Michael Skipworth as successor CEO, effective March 13, 2022. Charlie resigned from the company to become CEO of Salad And Go, where he serves on the Board of Directors. Lynn Crump-Caine, the Lead Independent Director, was appointed to succeed Charlie as Chair.

16:01 EDT Spruce Biosciences names Will Charlton as Chief Medical Officer - Spruce Biosciences "announced that Will Charlton, M.D., M.A.S., has been appointed Chief Medical Officer, and will succeed Rosh Dias, M.D., who has stepped down to pursue other opportunities. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of clinical research experience in industry and academia and will lead the company's clinical development and global drug development strategy."

15:19 EDT Twitter switches timeline back so users see latest tweets first - Twitter's support account tweeted: "We heard you -- some of you always want to see latest Tweets first. We've switched the timeline back and removed the tabbed experience for now while we explore other options." Reference Link

14:02 EDT Valaris: VALARIS DS-16 broke free from moorings on Saturday, then secured - Valaris Limited confirmed that drillship VALARIS DS-16, which is currently undergoing reactivation activities at ST Engineering Halter Marine and Offshore shipyard in Pascagoula, Mississippi, in advance of its next contract, broke free from its moorings during gale force winds in the early hours of Saturday, March 12. Valaris said: "The rig was promptly secured and safely returned to its mooring location the same day. There were no injuries, no environmental impact and only minor damage to the rig as a result of the event. Valaris continues to work closely with the relevant authorities and its customer and does not expect any delays to the contract commencement as a result of the incident."

13:37 EDT Comscore turns positive, up 5% after report of Nielsen talks to be bought - Shares of comScore (SCOR) are off their lows and have turned positive, rising 12c, or 5% to $2.66 in afternoon trading after The Wall Street Journal said that a consortium of private equity firms including Elliott Management is in talks to buy audience measurement rival Nielsen (NLSN) for about $15B including debt.

13:24 EDT Nielsen trading resumes

13:21 EDT Nielsen jumps 3% to $18 after WSJ report of Elliott consortium takeover talks

12:25 EDT CDC lowers cruise COVID risk level to 'Moderate' from 'High' - The Centers for Disease Control and Prevention lowered the cruise ship COVID-19 Travel Health Notices from Level 3, "High," to Level 2, "Moderate." Level 2 is "Moderate," two notches the "Very High" risk of Level 4. "The THN for cruise ship travel represents the status of the COVID-19 pandemic at this time. For travelers booking cruise travel now, be aware that the level may change as the COVID-19 pandemic evolves and may be different by the time of your cruise," the agency said on its website. Companies in the cruise space include Norwegian Cruise Line (NCLH), Carnival (CCL) and Royal Caribbean (RCL). Reference Link

12:00 EDT Independence Contract Drilling falls -15.3% - Independence Contract Drilling is down -15.3%, or -84c to $4.66.

12:00 EDT MultiPlan falls -29.9% - MultiPlan is down -29.9%, or -$1.47 to $3.44.

12:00 EDT Sonendo rises 17.0% - Sonendo is up 17.0%, or 53c to $3.65.

11:55 EDT Blonder Tongue Laboratories trading resumes

11:40 EDT Blonder Tongue Laboratories trading halted, news pending

11:07 EDT Newegg signs NCAA athlete endorsement deal with Carr Reese - Newegg announced it has signed an NCAA athlete endorsement, the company's first, with elite women's college basketball player Cate Reese of the University of Arizona for a promotional campaign starting today and continuing during the 2022 women's NCAA basketball tournament.

10:52 EDT Sunlands Technology Group (Class A ADS) trading resumes

10:25 EDT Lilium down 21% after Iceberg Research publishes short report

10:00 EDT Peabody Energy falls -13.6% - Peabody Energy is down -13.6%, or -$3.12 to $19.90.

10:00 EDT MultiPlan falls -18.0% - MultiPlan is down -18.0%, or -88c to $4.02.

10:00 EDT FirstMark Horizon Acquisition Corp. rises 15.4% - FirstMark Horizon Acquisition Corp. is up 15.4%, or $1.23 to $9.18.

09:55 EDT IXHL Stock trading resumes

09:47 EDT XPeng falls -13.2% - XPeng is down -13.2%, or -$3.02 to $19.89.

09:47 EDT KE Holdings falls -16.2% - KE Holdings is down -16.2%, or -$1.63 to $8.41.

09:47 EDT Valens Semiconductor rises 9.3% - Valens Semiconductor is up 9.3%, or 52c to $6.10.

09:43 EDT HollyFrontier, Holly Energy Partners establish HF Sinclair Corporation - HollyFrontier Corporation (HFC) and Holly Energy Partners, L.P. (HEP) announced the establishment of HF Sinclair Corporation (DINO) as the new parent holding company of HollyFrontier and HEP and the completion of their respective acquisitions of Sinclair Oil Corporation and Sinclair Transportation Company from The Sinclair Companies. Commencing at market open on March 15, 2022, HF Sinclair will replace HollyFrontier as the public company trading on the New York Stock Exchange, and will trade under the ticker symbol "DINO" and under the new CUSIP number 403949 100. HF Sinclair will be the parent company of a leading integrated downstream petroleum and renewable fuels company with enhanced scale and a strong marketing presence featuring: An expanded refining business that includes seven complex refineries across the Mid Continent Southwest, Rocky Mountain and Pacific Northwest that convert discounted, heavy and sour crudes into a high percentage of gasoline, diesel and other high value refined products. A growing renewables business with three production facilities that are expected to produce approximately 380 million gallons of renewable diesel annually. A multi-national lubricants business that produces specialty products and base oils, marketed under the Petro-Canada Lubricants, Sonneborn, Red Giant Oil and HollyFrontier Specialty Products brands. A leading marketing business, featuring the Sinclair brand and comprising 300-plus distributors and more than 1,300 independent wholesale branded sites located across 30 states. An expansive logistics business under HEP with an integrated logistics network connecting key crude and product regions and interests in strategic joint ventures that provide access to finished product pipelines and storage. Across its businesses, HF Sinclair will build on its legacy companies' ongoing ESG efforts with increased renewables scale, a shared commitment to health and safety practices that best serve employees and communities, and a focus on risk management. With the addition of Sinclair's integrated crude and refined products midstream business, HEP significantly extends the reach of its network of pipelines and storage facilities, enhancing its earning power to capture new organic growth opportunities and expects to increase cash returns to unitholders. HollyFrontier's senior management team will continue to operate HF Sinclair, which is headquartered in Dallas, Texas, with combined business offices in Salt Lake City, Utah. HEP's senior management team will continue to operate HEP under the name Holly Energy Partners, L.P. Pursuant to an agreement between HollyFrontier and Sinclair, Ross Matthews and Norman Szydlowski will be appointed to the HF Sinclair Board of Directors effective March 15, 2022. Collectively, the appointees have over 60 years of energy industry experience. Mr. Matthews served as Chairman and CEO of Sinclair Oil Corporation from October 2009 until the closing of the transaction. Mr. Szydlowski previously served as CEO of SemGroup Corporation, Rose Rock Midstream and Colonial Pipeline Company and as Director of Sinclair Oil Corporation. Additionally, pursuant to an agreement between HEP and Sinclair, Mark Peterson will be appointed to the Holly Logistics Services, L.L.C. Board of Directors. Mr. Peterson has over 30 years of experience in the midstream sector and served as Vice President, Transportation for Sinclair Oil Corporation from January 2010 until the closing of the transaction and Director and President of Sinclair Transportation Company from August 2009 until the closing of the transaction. In connection with the close of the transaction, all existing shares of HollyFrontier have automatically converted on a one-for-one basis into shares of common stock of HF Sinclair, and HF Sinclair has issued approximately 60.2 million shares of common stock to Sinclair, representing 27% of the pro forma equity of HF Sinclair with a value of approximately $2.1 billion based on HollyFrontier's fully diluted shares of common stock outstanding and closing stock price on March 11, 2022. HEP has also issued 21 million common units to Sinclair, representing 17% of the outstanding common units, and having a value of approximately $349 million based on HEP's fully diluted common units outstanding and closing unit price on March 11, 2022.

09:40 EDT Poet Technologies commences trading on Nasdaq - POET Technologies announced that the Company's common shares have commenced trading on the Nasdaq Capital Market under the symbol "POET" as of market open today, March 14, 2022. The Company will continue to maintain its existing listing and trading symbol "PTK" on the TSX Venture Exchange. For the avoidance of doubt, no action is required by existing shareholders associated with the Nasdaq listing.

09:37 EDT Nektar trading resumes

09:35 EDT MEDIROM Healthcare Technologies Inc (ADS) trading resumes

09:32 EDT Nektar trading halted, volatility trading pause

09:31 EDT APA Corp. closes two transactions, receives $1B of proceeds - APA Corporation (APA) announced the closing of two transactions, generating net proceeds of approximately $1 billion. On March 7, subsidiaries of the company completed the sale of a Delaware Basin mineral package to an undisclosed buyer for approximately $805 million, subject to post-closing adjustments. The divested assets primarily comprise non-operated properties across west Texas and southeast New Mexico, with estimated production of approximately 7,000 barrels of oil equivalent per day. In a second transaction, on March 11, a subsidiary of APA completed the sale of 4 million shares of Kinetik (KNTK) Class A common stock for net proceeds of $224 million. The transaction follows the combination of Altus Midstream and BCP Raptor Holdco LP that formed Kinetik and was completed in late February. Within the next 24 months, Apache will invest a minimum of $100 million for new well drilling and completion activity at the Alpine High play in the Delaware Basin, where Kinetik has exclusive gas and NGL gathering and processing rights.

09:30 EDT IXHL Stock trading halted, volatility trading pause

09:28 EDT Sono Motors enters series-validation phase - Sono Motors is currently building a fleet of series-validation vehicles, ushering in the Sion's testing program. These cars consist of series components and correspond to the planned final design, which was established at the beginning of the year alongside completion of the 2nd generation prototype program and the accompanying definition of components as well as vehicle parameters. In the coming months Sono Motors will be undertaking testing, validation and certification of the Sion, until the first affordable solar electric vehicle for the masses rolls off the production line, expected next year. The test cars will undergo uncompromising practical tests under extreme conditions in Europe and the U.S. This includes testing in different climates, optimizing our solar technology and safeguarding, as well as refining driving dynamics on test tracks and on public roads in addition to crash tests. . The fleet of 37 vehicles consists of 16 complete cars and 21 test structures. The public debut for the Sion's final design is planned for the summer of 2022. Then some of the series-validation vehicles will most likely additionally go on a Europe-wide test drive tour. Sono Motors will be supported by thyssenkrupp Automotive Body Solutions and Betrandt in series-validation vehicle production. Markus Volmer, CTO of Sono Motors says, "Both partners have not only extensive expertise in automotive engineering but also the necessary infrastructure and capacity to produce our test cars quickly and with high quality. Thus, we are on track for the Sion testing." As an expert in integrated body construction solutions, thyssenkrupp Automotive Body Solutions is responsible for the production of the aluminum space frame. Bertrandt impresses with decades of experience in the field of integrated vehicle development and is responsible for the assembly of the Sion test fleet in Munich. At an estimated sales price point of just 28,500 euros gross, the Sion will be the first affordable SEV. The outer shell of this family-friendly car will consist of 458 seamlessly integrated solar half-cells and will enable self-sufficiency on short journeys. The energy generated by the solar cells will extend the range of the Sion's 54-kWh LFP battery by an average of 112 km per week. Commuters in metropolitan areas thus ideally have to charge their Sion four times less than conventional electric cars of the same vehicle class with a similar battery size. Bidirectional charging technology complements the car's solar integration and is designed to turn the Sion into a sustainable power plant on wheels that will be able to power electronic devices, the home or other electric cars with an output of up to 11 kW.

09:26 EDT Farmer Bros. releases updated investor presentation, provides business update - Farmer Bros. released an updated investor presentation containing recent business updates. "Turnaround taking hold." Despite Global Headwinds, Operating Efficiency Initiatives Are Taking Hold, As Evidenced By: Continued gross margin expansion despite inflationary headwinds; Margins inline with pre-COVID, despite lower DSD volumes; Dallas/Ft. Worth roasting facility output at the highest level in history, with potential for expansion; Recent price increases beginning to flow through P&L; Expected to be significantly more impactful beginning F3Q; Expected bottom-line benefit from cost-plus nature of DS; DS improvement driven by recently-optimized customer base & recovery of several larger accounts. Sustained Margin Expansion & Increased Volumes - On average, it takes ~45 days for price increases to flow through due to customer obligations & a 30-day grace period. Similarly, there's a 30- to 90-day contractual lag before we can pass through DS costs to customers. Unaudited - At F2Q-end, GM expanded greater than400bps Y/Y to 29.5%; the strongest since F2Q of 2019-prior to onset of COVID. "Direct-Store-Delivery Update:" Sales Volumes - F2Q marked our 6th consecutive quarter of growth; YTD has hovered in the (14)% to (17)% range(1); impacted by holidays & regional weather issues; nationally now within (5)% to (10)% with some individual regions performing even better. Operations: Consumer behaviors normalizing despite lingering labor & supply issues; Inventory stocking improved; Transportation & rerouting efforts producing more efficient freight expenses; Customer base & order size continuing to expand; Won several smaller, regional contracts YTD; wins expected to accelerate as COVID further recedes

09:23 EDT APA Corp. commences cash tender offer for up to $500M of notes - Apache Corporation announced today that it has commenced cash tender offers to purchase up to $500 million in aggregate principal amount of its outstanding notes. Subject to the Maximum Purchase Amount, the amount of a Series of Notes that is purchased in the Offers will be based on the Acceptance Priority Levels. The Offers are being made on the terms and subject to the conditions set forth in the offer to purchase dated March 14, 2022. Capitalized terms used in this release but not otherwise defined have the meaning given in the Offer to Purchase. Consummation of the Offers and payment for the Notes accepted for purchase are subject to the satisfaction or waiver of certain conditions described in the Offer to Purchase, including the Maximum Purchase Condition, as well as other customary conditions. Subject to applicable law, Apache has reserved the absolute right to, in its sole discretion, at any time, waive any and all conditions to the Offers, extend, terminate, or withdraw any Offer or the Offers, increase the Maximum Purchase Amount or waive the Maximum Purchase Condition, with or without extending the Withdrawal Time, or otherwise amend the Offers in any respect. The Offers will expire at 5:00 p.m., New York City time, on March 18, 2022, unless extended or earlier terminated as described in the Offer to Purchase. Holders of the Notes may withdraw their validly tendered Notes at any time at or prior to 5:00 p.m., New York City time, on March 18, 2022, unless extended. Holders are urged to read the Offer to Purchase carefully before making any decision with respect to the Offers.

09:21 EDT Agrify secures $135M debt facility - Agrify Corporation announced that it has entered into a debt financing agreement for up to $135 million in a Senior Secured Note facility with an institutional lender. The proceeds will be used for working capital and general corporate purposes. An initial funding of $65 million under the Note will be immediately available to the Company at an initial closing, with the option for the Company to draw down the remaining $70 million available in two subsequent fundings of $35 million each, subject to the satisfaction of certain funding conditions.

09:20 EDT Wesana Health announces feedback from pre-IND meeting on SANA-013 - Wesana Health Holdings announced that they have received a full written response from the Food and Drug Administration regarding their pre-Investigational New Drug meeting for the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury related major depressive disorder. The Company received positive written responses from the FDA on March 11th outlining the requirements to open the IND and commence with clinical studies for SANA-013. The Company believes the written response provides a path to agreements on IND-enabling studies and validates the team's effort and accomplishments over the past year. Wesana intends to initiate its in-human clinical study program in late 2022. The FDA response also provided important insights pertaining to advancing SANA-013 as a potential treatment for TBI-related MDD. SANA-013 is covered under patent applications owned by Wesana and directed to novel composition and novel methods of use. Patent applications detail the use of a loading dose of psilocybin and a maintenance dose of psilocybin given concomitantly with a dose of cannabidiol. This novel combination therapy has demonstrated effectiveness through different and potentially complementary pharmacologic pathways. Unlike therapist assisted, single dose therapy, where a large dose of psilocybin is administered in clinic, which has exhibited poor durability and waning effects beginning as early as a few weeks post administration, SANA-013 is being developed to utilize a loading dose of psilocybin followed by self-administered maintenance doses of psilocybin and CBD to provide more sustained effects and benefit over time.

09:19 EDT WSFS Bank names twelve associates to senior leadership - WSFS Bank announces that the following 12 Associates from across the organization have been elevated to Senior Vice President, SVP, positions: Rebecca Acevedo - SVP, Director of Corporate Communications; Laura Almeda - SVP, BSA/OFAC Officer; Patrick Best - SVP, Director of Talent Acquisition; Michelle Burroughs - SVP, Chief Diversity Officer; Dana Di Bruno - SVP, Digital Business Strategy Manager; Matthew Glanden - SVP, Credit Quality & ACL Director; Marylynne Hoffman - SVP, Director of Retail Operations; Nicholas Leati - SVP, NCino Product Owner; Christopher Scarpitti - SVP, Senior Relationship Manager, Middle Market; Scott Sukeena - SVP, Senior Relationship Manager; Phanny Torn - SVP, Director of Loan Production and Fulfillment; and Carolyn Urbanovich - SVP, Regional Manager. "The continued professional development and advancement of these Associates speaks to WSFS' strong culture and focus on building a robust leadership pipeline," said Michael Conklin, Executive Vice President and Chief Human Resources Officer. "These Associates have embraced opportunities to challenge themselves, and are a key part of helping to grow our Company. We congratulate them on this recognition and look forward to their continued contributions to our Customers, Communities and Company."

09:18 EDT GeoVax Labs retains CATO SMS to manage two phase 2 COVID-19 vaccine trials - GeoVax Labs (GOVX) announced the engagement of CATO SMS to manage GeoVax's two ongoing Phase 2 clinical trials of its vaccine candidate, GEO-CM04S1, against SARS-CoV-2. David Dodd, GeoVax President and CEO, commented, "We are excited to have engaged CATO SMS as our CRO partner for our advancing clinical studies of GEO-CM04S1. CATO SMS brings deep experience in the area of infectious disease including managing COVID-19 clinical trials. We previously announced the engagement of CATO to manage our Phase1/2 trial of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma, and now look forward to working with them for our COVID-19 vaccine trials as well to achieve important clinical milestones including the expansion of clinical sites and acceleration of patient enrollment and evaluation."

09:17 EDT National Energy Services to restate financial statements for 2018, 2019, 2020 - On March 10, 2022, subsequent to the companywide adoption of a new SAP ERP system and the ensuing ongoing reconciliation process, the management of National Energy Services Reunited Corp. concluded and recommended to the Audit Committee of the Company's Board of Directors, and the Audit Committee agreed, that the Company's consolidated U.S. GAAP financial information and related disclosures for the fiscal year ended December 31, 2018, December 31, 2019 and December 31, 2020 filed with the United States Securities and Exchange Commission , contain errors primarily related to accounts payable reconciliations and accrued liabilities. Therefore, the U.S. GAAP statements for the foregoing years will need to be restated and should no longer be relied upon. The Company is working to determine whether these issues also have any material impact on the financial statements for the unaudited quarterly financial statements for the first three quarters of 2021. Based on a preliminary analysis, the Company currently believes that the aggregate amount of the restatement, for all of the impacted and potentially impacted time periods, will be in the range of $60 to $90 million. The Company's management and Audit Committee have discussed the same with KPMG Assurance and Consulting Services LLP, the Company's former independent public accounting firm, as well as PricewaterhouseCoopers the Company's present independent public accounting firm that will be conducting the 2021 audit. Members of the Audit Committee of the Company's Board of Directors are overseeing the process of addressing these findings as the Company works diligently to understand and address the causes of this issue and finalize the effects of the reconciliations and subsequent restatements. The Company is working to file restated financial statements related to prior periods as soon as practicable.

09:16 EDT Illumina names Carissa Rollins as Chief Information Officer - Illumina (ILMN) announced that Carissa Rollins will join the company as Chief Information Officer on March 14. Rollins brings over 30 years of business technology transformation and digital and consumerization strategy experience. Rollins will report to CEO, Francis deSouza. Most recently, Rollins was the Chief Information Officer at UnitedHealthcare (UNH).

09:13 EDT Sky appoints Paul Chernawsky as chair of Insurance Advisory Board Committee - SQL Technologies announced that Paul Chernawsky, founder, and former CEO of Endurance, who invested SKY's IPO, will Chair Sky's Insurance Advisory Board Committee.

09:11 EDT Aerojet Rocketdyne holder Steel Partners urges support of director nominees - Steel Partners Holdings which owns approximately 5.2% of the outstanding shares of Aerojet Rocketdyne (AJRD) Holdings and has nominated seven highly qualified candidates for election to the Company's Board of Directors at the 2022 Annual Meeting of Shareholders ssued the following letter: Fellow Shareholders, Steel Partners is one of the largest shareholders of Aerojet Rocketdyne, with ownership of approximately 5.2% of the Company's outstanding shares. We are also a long-term shareholder that has spent nearly 15 years supporting the Company's efforts to evolve and produce enhanced value. We believe our sizable ownership interest in Aerojet Rocketdyne and record of helping drive total shareholder returns of more than 250% since receiving boardroom representation should signal that Steel Partners' interests are squarely aligned with your interests. We recently nominated seven highly qualified director candidates, including four sitting Board members with extensive business leadership experience and strong track records of value creation, for election to Aerojet Rocketdyne's Board at this year's Annual Meeting. We believe the four other sitting Board members, including Chief Executive Officer Eileen Drake and the incumbents she has purportedly nominated, failed shareholders over the past year by not effectively planning for a world in which the Lockheed Martin (LMT) transaction did not go through. We remain confounded by the fact that Ms. Drake and her faction ignored our calls for contingency planning as regulatory headwinds mounted and it became clear the Lockheed Martin transaction was in jeopardy. That is why we took the extraordinary step of nominating a slate ahead of the deal ultimately being terminated.

09:10 EDT Mercer announces retirement of CEO David Gandossi, Juan Carlos Bueno to succeed - Mercer International announced that David Gandossi, who has served as CEO and President since 2015, has announced, as part of turning 65 years old this year, his decision to retire from the Company. The Board of Directors has appointed Juan Carlos Bueno to succeed Mr. Gandossi as Chief Executive Officer and President effective May 1, 2022. He will also be nominated for election to the Company's Board of Directors at the upcoming 2022 annual general meeting of shareholders. Gandossi will step down from his current executive duties after more than seven years as CEO and President concurrently with Mr. Bueno's appointment. He will continue with the Company as an advisor until August 31, 2022 and assist Mr. Bueno and Mercer to facilitate a smooth transition. Bueno most recently served from 2018 to the present date as the Chairman of the Board and co-founder of Global Energy which produces novel green energy generation devices.

09:07 EDT WidePoint appoints Robert George as CFO - WidePoint has appointed Robert George as CFO who will officially take role on April 1. George replaces Kellie Kim, who previously announced her retirement in November 2021. George brings more than 30 years of business experiences ranging from entrepreneurial companies to publicly traded multinational corporations. He most recently served as CFO of Exovera, a SOS International subsidiary.

09:07 EDT Philips showcases health informatics solutions at HIMSS22 - Royal Philips will showcase its latest secure, connected and scalable informatics solutions during the HIMSS22 Global Health Conference & Exhibition. Philips will share its deep clinical and operational expertise to support healthcare providers' digital transformations and showcase its informatics suite that delivers data-driven actionable insights to advance precision care, support care along each patient's pathway and improve transitions across care settings. Philips will spotlight how its integrated solutions address some of the most urgent needs that the industry faces today, including staff shortages and cybersecurity threats.

09:06 EDT Beacon announces $125M accelerated share repurchase agreement - Beacon announced that it has entered an accelerated share repurchase agreement, or ASR, with Citibank N.A to repurchase $125M of Beacon's common stock. The ASR accelerates Beacon's progress under its $500M share repurchase program announced February 24.

09:05 EDT Beacon Properties Corporation announces $125M ASR - Beacon announced that it has entered an accelerated share repurchase agreement, or ASR, with Citibank N.A to repurchase $125M of Beacon's common stock. The ASR accelerates Beacon's progress under its $500M share repurchase program announced February 24.

09:04 EDT WISeKey signs strategic partnership agreement with Synergy Quantum - WISeKey International announces the signing of a strategic partnership with Synergy Quantum SA, a Swiss based quantum technology company that offers high impact Industry solutions using Quantum technologies, and has developed a technology that protects private data with post-quantum end-to-end encryption. The purpose of the partnership is to offer the financial services industry two-factor authentication based on current and new post-quantum WISeKey semiconductors in combination with Synergy Quantum post-quantum encryption solutions. WISeKey and Synergy Quantum will co-develop post-quantum NFC/ID card solutions for second factor identification and post-quantum encryption chips and software platform for PQE tunnelling solutions. Of note, in October 2021, Synergy Quantum SA signed a joint venture agreement with the I-Hub Quantum Technology Foundation, under the National Mission for Interdisciplinary Cyber Physical Systems, Ministry of Science and Technology, Government of India to provide its knowhow and skills for the productization and commercialization of co-developed technologies in the field of quantum sciences.

09:04 EDT NextNav adds Mortimer as VP of Government Affairs, Lantz as General Counsel - NextNav announced the addition of two new hires to its leadership team, with Ed Mortimer joining as Vice President, VP, of Government Affairs and Robert Lantz as General Counsel. Mortimer joins NextNav's executive team as Vice President of Government Affairs, bringing over thirty years of experience in infrastructure legislation and regulation to the team. Most notably, Mortimer served as the Vice President of Transportation and Infrastructure for the United States Chamber of Commerce from 2015 to 2022. In addition to Mortimer, Robert Lantz, an attorney with over two decades of legal experience in the public and private technology and telecommunications space, joins NextNav after supporting the company l through its merger with Spartacus Acquisition Company.

09:03 EDT PennantPark Floating Rate increases commitment to joint venture - PennantPark Floating Rate Capital (PFLT) announced that its unconsolidated joint venture with a subsidiary of Kemper Corporation (KMPR), Trinity Universal Insurance Company, have agreed to increase its capital commitments to the PennantPark Senior Secured Loan Fund I LLC, PSSL, from $278.0 million to $343.0 million. PFLT's portion of this capital commitment increase is $56.9 million, which includes $39.8 million of Senior Secured Notes and $17.1 million of Capital Commitments. The joint venture which was created in 2017 and primarily invests in U.S. middle-market companies whose debt is rated below investment grade.

09:02 EDT Arcimoto, Scoot Scoot Rentals begin FUV rentals in St. Petersburg, Florida - Arcimoto and Scoot Scoot Rentals announced that they will begin renting Arcimoto Fun Utility Vehicles in St. Petersburg, Florida, beginning in March.

09:00 EDT Heico's Lucix acquires Flight Microwave Corporation, terms not disclosed - HEICO Corporation announced that its Lucix subsidiary acquired 100% of the stock of Flight Microwave Corporation in an all cash transaction. Further financial terms and details were not disclosed. HEICO stated that it expects the acquisition to be accretive to its earnings in the year following the purchase. Founded in 2004, Flight Microwave is a leading designer and manufacturer of world class custom high power filters and filter assemblies used in space and defense applications. Among Flight Microwave's most recognized products are the high power, space-borne filter payload assemblies used on the Global Positioning System's GPS III program as well as other key US Government satellite payloads. Flight Microwave's design and production center is located in El Segundo, CA. With a significant heritage on many leading satellite programs dating back to 2004, Flight Microwave is known as a pioneer for consistently developing products that lead the industry in performance, innovation and quality. Flight Microwave will operate as part of Lucix and will eventually relocate to Lucix's Camarillo, CA headquarters, engineering and production center. Nearly all of Flight Microwave's team will remain with the business post-closing.

08:58 EDT Smith-Midland says J-J Hooks barriers awarded updated approval by Florida DOT - Smith-Midland Corporation announced that The Florida Department of Transportation awarded Easi-Set Worldwide an updated approval for the MASH tested J-J Hooks "Type K" 12.5-foot portable concrete barrier, which now allows the previously approved anchored barrier, staked or bolted, to also be used in a freestanding application. The multi-functional "Type K" J-J Hooks barrier, which is specific to FDOT, allows Florida contractors to use the same product for all applications, eliminating the need for specialized inventory.

08:55 EDT Musk: Tesla, SpaceX seeing 'significant' recent inflation pressure - Elon Musk said via Twitter on Sunday night: "Tesla & SpaceX are seeing significant recent inflation pressure in raw materials & logistics." Reference Link

08:54 EDT AAR Corp. signs exclusive distribution agreement with Collins Aerospace - AAR has signed an exclusive distribution agreement with Collins Aerospace's Goodrich De-Icing & Specialty Heating Systems business. Through this agreement, AAR will provide airlines, other aircraft operators, and MROs globally with de-icers and supporting products. Product offerings include patented technology and are predominantly used on general aviation aircraft, regional turbo-prop aircraft, and most multi-engine piston business aircraft.

08:50 EDT Navitas Semiconductor GaNFast technology selected for Samsung Galaxy S22 - Navitas Semiconductor (NVTS) has announced that its GaNFast technology has been selected for Samsung's (SSNLF) flagship Galaxy S22 Ultra and S22+ smartphones. The small, powerful 45W Super Fast charger has the highest power density of any Samsung charger, enabled by GaNFast power ICs.

08:45 EDT Omniq announces rollout of 1,000 units of SBG solution for supermarket chain - OMNIQ Corp., announced the rollout of 1,000 units of the Smart Buy and Go solution for one of Israel's largest supermarket chains by Dangot Computers Ltd, a subsidiary of OMNIQ. The Company plans to offer its SBG solution to its customers in the United States.

08:43 EDT Stem appoints Kim Homenock Chief People Officer - Stem announced the addition of Kim Homenock to the Stem leadership team as Chief People Officer. Homenock brings 20 years' experience in senior human resources leadership positions. At Stem, Homenock will oversee the global HR team with a focus on organizational development, global talent acquisition, training, and enhancing the employee experience for more than 500 Stem employees.

08:43 EDT Abcam increases CY24 revenue goal target range to GBP 450M-GBP 525M - CY2024 revenue goal target range increased by GBP 25m to GBP 450m-GBP 525m, adjusted to incorporate BioVision and current operating performance; Adjusted operating margin and ROCE targets remain unchanged.

08:41 EDT Ideal Power appoints two independent members to board of directors - Ideal Power (IPWR) announced that its Board of Directors appointed two new independent members, Drue Freeman and Greg Knight, to the Board. As a result of these appointments, Ideal Power's Board will increase in size from three to five members, four of whom are independent. Freeman has over 30 years of semiconductor industry experience, 16 of which focused on sales and marketing of semiconductors to the automotive industry. He spent most of his career at NXP Semiconductors (NXPI). Knight has 20 years of experience in the photovoltaic, silicon carbide, EV and power electronic markets in both leadership positions and as a strategic consultant. He most recently served as President and Chief Executive Officer of GT Advanced Technologies.

08:40 EDT GreenPower Motor appoints RWC Group as a dealer for BEAST school bus - GreenPower Motor Company announced the appointment of the RWC Group as a dealer for GreenPower's BEAST school bus in the states of Arizona and Washington and Clark County in Nevada with approximately 20,000 school buses in these regions. RWC Group will take delivery of two GreenPower BEAST school buses in April and has committed to at least 12 more BEAST school buses in the first year.

08:37 EDT Virtu, Arqaam announce co-operation to deploy Virtu's algorithms in MENA markets - Virtu Financial announced a non-exclusive co-operation agreement with emerging markets specialist Arqaam Capital to deploy Virtu's global equity execution algorithms to clients in Middle-Eastern and North Africa, MENA, markets. Under the collaboration, Arqaam will provide market access, settlement and local expertise in MENA equity markets to Virtu clients and Arqaam clients will be able to leverage Virtu's suite of trading algorithms to access global markets, including MENA. "This co-operation extends Arqaam's local market access and expertise to Virtu's global client base and further demonstrates Virtu's commitment to clients who want to execute and settle in the MENA region. Given our history, Arqaam was the logical collaboration choice as we work to expand the MENA market coverage of Virtu's equity algorithms," said Rob Boardman, CEO Virtu Financial EMEA. "The global reach and scale of Virtu's algorithmic trading platform combined with Arqaam's MENA market access and local expertise has powerfully enhanced our respective execution platforms-providing our clients with greater optionality."

08:36 EDT Reed's announces closing of $5.4M private placement - Reed's announced the closing of its previously announced private placement with certain institutional and accredited investors of 18,594,571 shares of common stock and warrants to purchase up to an aggregate of 9,297,289 shares of common stock, for an aggregate gross proceeds of $5.4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Officers and directors of the Company purchased approximately $1.1 million of the securities in the offering. The purchase price per share of common stock and associated warrant was $0.28 for the investors and $0.3502 for the officers and directors of the Company in compliance with the rules of the Nasdaq Stock Market. Each whole warrant entitles the holder to purchase one share of common stock at an exercise price of $0.2877 per share. The warrants become exercisable six months from today and are exercisable for a period of five years. Roth Capital Partners acted as the sole placement agent for the offering. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

08:35 EDT Mammoth Energy issues statement on Puerto Rico bankruptcy developments - Mammoth Energy Services issued the following statement in response to Puerto Rico's governor Gov. Pedro Pierluisi's attempt to terminate the $8.3B dollar bankruptcy agreement that would have allowed the Puerto Rico Electric Power Authority to emerge from bankruptcy and pay its creditors: "This is yet another example of Puerto Rico and PREPA continuing their resistance to pay their bills. I commend Judge Laura Taylor Swain for directing the Puerto Rico Fiscal Management and Oversight Board to advance a new deal for PREPA immediately. While PREPA has begun addressing amounts owed to post-bankruptcy creditors, Mammoth's subsidiary Cobra Acquisitions LLC is still owed more than $340 million dollars for work completed nearly three years ago. PREPA is running out of excuses, and it is well past time for them to make their creditors whole," said Arty Straehla, CEO of Mammoth.

08:33 EDT Danaos placed orders for two 7,100 TEU containerships - Danaos announced that it has placed orders for two 7,100 TEU containerships. The vessels will be built at Dalian Shipbuilding in China and are expected to be delivered to Danaos in the 2nd and 3rd quarter of 2024. The counterparties of Danaos to the shipbuilding contracts, Dalian Shipbuilding and CSTC are both subsidiaries of CSSC, one of the world's largest shipbuilding groups. The vessels will be methanol fuel ready and will be built in accordance with the latest requirements of the International Maritime Organization in relation to Tier III emission standards and Energy Efficiency Design Index Phase III.

08:33 EDT Sypris CFO Anthony Allen to transition out of role, Richard Davis to succeed - Sypris Solutions announced the appointment of Richard Davis, the company's VP, to the position of VP and CFO effective October 12. Davis will remain located in Louisville, Kentucky and will report to Jeffrey Gill, the company's chairman, president and CEO. Davis has served as VP of Sypris since January 2018 and as VP audit and compliance from August 2015 to December 2017. Davis will succeed Anthony Allen, the company's current VP and CFO, who will serve as VP and treasurer effective October 12.

08:31 EDT Lazydays unanimously rejects proposal from B. Riley Financial - Lazydays Holdings (LAZY) announced that its Board of Directors has unanimously rejected the B. Riley (RILY) non-binding, unsolicited proposal to acquire the company for $25.00 per share, as set forth in the B. Riley March 9 public letter. The Lazydays Board of Directors appreciates the interest that B. Riley has expressed in the company. The Board has carefully reviewed the B. Riley proposal with the assistance of its advisors and, after thorough consideration in accordance with its fiduciary duties, has determined that the proposal meaningfully undervalues the company and is not in the best interests of shareholders. "The Board will continue to take seriously all credible interest in Lazydays, however we do not believe that now is an advantageous time to actively pursue a sale of the business. We are confident in the company's strategic direction, management team, balance sheet, shareholder base and industry partners. Upon this strong foundation, we see a compelling opportunity over the coming years to create considerable shareholder value," said Chris Shackelton, Lazydays Chairman of the Board.

08:29 EDT Rivian Automotive hires Frank Klein as COO - Rivian Automotive announced the hiring of Frank Klein as COO, effective June 1. Frank most recently held the position of president at Austria-based automotive contract manufacturer Magna Steyr, a subsidiary of Canadian-based Magna International. He will be based in Normal, Illinois, and will report directly to Rivian's CEO, RJ Scaringe. Klein succeeds Rod Copes, who retired from the position last year.

08:28 EDT Solid Biosciences reports efficacy, safety data from Phase I/II IGNITE DMD trial - Solid Biosciences provided an update from the ongoing IGNITE DMD Phase I/II clinical trial, as well as a business and financial update. The company reported two-year efficacy and safety data from the first three patients treated in the high dose cohort of the ongoing Phase I/II IGNITE DMD clinical trial. Additionally, the company reported 90-day biopsy results for Patients 7-9, the most recent three patients treated in the high dose cohort. Roxana Donisa Dreghici, MD, Senior Vice President, Head of Clinical Development at Solid will present "IGNITE DMD Phase I/II Study of SGT-001 Microdystrophin Gene Therapy for DMD: 2-Year Outcomes Update" in an oral session at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference on Wednesday, March 16. The conference is taking place March 13-16 in-person in Nashville and virtually. The company reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose cohort as part of IGNITE DMD. Results suggest durable benefit 24-months post-administration of SGT-001, when compared to natural history. These data are consistent with results reported at the 12-month and 18-month time periods for the same patients. The average age of Patients 4-6 at the two year timepoint was 10.4 years. Data from Patients 4-6 suggest improved motor function at two years post-infusion, as assessed by 6-Minute Walk Test and North Star Ambulatory Assessment, against expected natural history declines. In addition, the data suggest improved pulmonary function, as measured by forced vital capacity and peak expiratory flow, and sustained or improved patient reported outcome measures as assessed in key functional domains of the Pediatric Outcomes Data Collection Instrument when compared to both baseline and natural history. In addition, the company reported data from skeletal muscle biopsies collected three months after infusion of SGT-001 from the most recently dosed Patients 7-9. The range by immunofluorescence of 1% to 50% and by western blot of Below the 5% Limit of Quantification to 6.8%, were within the range of previously dosed Patients 4-6 in the high dose cohort. Microdystrophin expression levels for all six patients dosed in the high dose cohort ranged from 1 to 70% by immunofluorescence and BLQ to 17.5% by western blot. All six patients dosed with SGT-001 in the high dose cohort have demonstrated microdystrophin expression and proper membrane localization. No new drug-related safety findings have been identified in Patients 1-9 in post-dosing periods of 90 days to approximately four years. We continue to follow dosed patients and collect data to support the potential benefit of SGT-001. As previously disclosed, Solid is planning to conclude dosing patients as part of IGNITE DMD this year and begin End of Phase II discussions with the Food and Drug Administration.

08:23 EDT Marathon Gold purchases net profit interest royalty on Valentine Gold Project - Marathon Gold reports that it has purchased for cancellation the historical 7.5% net profit interest royalty that covers certain mineral resource areas at the Company's Valentine Gold Project in central Newfoundland. As consideration for the NPI Royalty, Marathon paid C$500,000 in cash and issued 1,341,607 common shares at closing to the Reid Newfoundland Company Limited, the private third-party vendor. Marathon has agreed to pay additional cash consideration of C$3 million to Reid upon the formal release of the Project from both the applicable provincial and federal environmental assessment processes. Matt Manson, President and CEO, commented: "The NPI Royalty that we purchased today relates to certain properties at the Valentine Gold Project referred to as the "Reid Lots". These properties were initially granted to the Reid Newfoundland Company Limited in the early part of the last century in connection with the development of the Newfoundland railway. The NPI Royalty, which was initially reserved in 1905 and amended in 1948 to provide for a 7.5% net profits interest royalty on all minerals, continues to apply today in the areas of the Leprechaun and Sprite Deposits and part of the Berry Deposit. Our acquisition of the NPI Royalty for cancellation is another key milestone as we progress the Valentine Gold Project towards a construction decision, and we are happy to welcome Reid as a Marathon shareholder."

08:22 EDT Industrial Logistics Property Trust names Yael Duffy COO - Industrial Logistics Properties Trust (ILPT) announced that Yael Duffy has been appointed as its President and Chief Operating Officer, effective April 1. Duffy has served as Vice President of ILPT since 2019 and as Vice President and Chief Operating Officer of ILPT since 2020. Ms. Duffy is also a Senior Vice President of The RMR Group (RMR), responsible for overseeing asset management of a portfolio of office, industrial and retail properties managed by RMR, as well as RMR's credit and business analytics teams. Ms. Duffy succeeds John Murray, who is becoming President and Chief Executive Officer of Sonesta International Hotels Corporation , effective April 1 . Mr. Murray has been a member of ILPT senior management since 2018 and he will continue to serve as a Managing Trustee of ILPT.

08:19 EDT Activision Blizzard partners with Aim Lab in multi-year sponsorship deal - Call of Duty League announced it has joined forces with Aim Lab as the official first-person training sponsor as well as the presenting sponsor of the Call of Duty Challengers Scouting Series. During the 2022 Call of Duty League season, Aim Lab will introduce a Best Shot segment, featuring best shot from all of the weekend's matches. Aim Lab will also present the Call of Duty Challengers Ticker, a new feature that appears at the bottom of viewers' screens to update fans on the results of Challengers matches during the Call of Duty League's broadcasts.

08:18 EDT BigCommerce and Bolt deepen pact to embed Bolt's 'One-Click Checkout' - BigCommerce announced, in strategic partnership with Bolt, a checkout and shopper network company, to now offer a brand new way for small-, medium-, and enterprise-sized BigCommerce merchants to set up Bolt One-Click Checkout in a self-serve manner within minutes. Bolt can easily be pre-built into merchants' BigCommerce stores allowing them to deliver secure, one-click transactions to create fast and seamless shopping experiences that move customers beyond the "buy" button, driving engagement and increasing conversion rates by up to 53%. "The last two years have accelerated changes in what consumers expect to get out of their shopping experience, where trends like buy online, pickup in-store , buy now, pay later and payments processing, are rapidly gaining traction. Having the right technology and infrastructure in place is essential for merchants to deliver on those expectations while focusing on the business at hand," said Russell Klein, chief commercial officer for BigCommerce. "Expanding availability of Bolt to all of our merchants will enable those store owners to further refine and optimize their checkout and overall conversion rates strategies, while still preserving their access to the myriad payment and other technology partner solutions that they also want to deploy."

08:17 EDT iCAD to showcase portfolio of Breat AI solutions at HIMSS 2022 - iCAD announced it will be showcasing its portfolio of Breast AI solutions, including ProFound AI for Digital Breast Tomosynthesis in the iCAD booth at the 2022 Healthcare Information and Management Systems Society, HIMSS, Global Health Conference & Exhibition in Orlando, FL, taking place March 14-18, 2022. "One of the most exciting developments in medicine is the use of artificial intelligence to detect, diagnose and improve efficacy of treatment," said Stacey Stevens, President and CEO of iCAD, Inc. "As the global leader in breast imaging AI, iCAD is playing an integral role. Our award-winning suite of Breast AI solutions for cancer detection, density assessment and risk evaluation help to significantly improve reading workflow while optimizing interoperability requirements with multi-vendor integrations. With our deep learning algorithms deployable on VMware vSphere and NVIDIA AI Enterprise, hospitals and centers can more effectively manage and scale our leading-edge breast health solutions." Experts from iCAD and NVIDIA will discuss how iCAD's flexible deployment options empower health systems to maximize their investment with the NVIDIA AI Enterprise software suite, combined with NVIDIA accelerated computing and VMware's virtual environment.

08:16 EDT Meten Edtechx unit enters cooperation framework agreement with Shengxue - Meten Holding Group announced that its subsidiary, Shenzhen Meten International Education Co., had entered into a strategic cooperation framework agreement on March 2 with Shenzhen Shengxue Culture Communication Co., Ltd, an online education and training institution focusing on the improvement of academic qualifications for adults. Shenzhen Meten and Shengxue expect to cooperate in development and design of new education products and marketing activities, in an effort to develop Shenzhen Meten's Metaverse education business. The goal of this strategic cooperation is to help qualified job seekers find their dream jobs in the fast-evolving labor market in China. The Chinese government is vigorously supporting the development of emerging industries, including modern services industry. With the emergence of these new industries, traditional education becomes less helpful to job seekers for obtaining those skills required by enterprises. Companies tend to seek talents with professional skills, comprehensive qualities, and practical skills. We believe that the shortage of professional talents in emerging technology industries, such as Metaverse-related industries, will gradually expand. On the other hand, as a result of the Chinese government's promotion of favorable policies and an increasing demand, the market size of the vocational education industry continues to increase year by year in China. According to data published by Qianzhan Industry Institute, the size of China's vocational education market was approximately $103B in 2021.

08:14 EDT Red Cat unit chosen by U.S. Army for SRR T2 drone program - Red Cat Holdings announces that its subsidiary Teal Drones has been selected by the Department of Defense's Defense Innovation Unit and U.S. Army to compete in the Short Range Reconnaissance Tranche 2 Program of Record. Teal was selected to develop a next-generation small unmanned aerial system designed for surveillance and reconnaissance duties, with a focus on autonomous capability, for the U.S. Army. The ultimate goal of the SRR T2 program is to provide a small, rucksack portable sUAS that gives all Army platoons with situational awareness beyond the next terrain feature. Following a successful demonstration in September 2021, Teal was notified by the U.S. Army's Short Range Reconnaissance Product Office that it would advance to the prototype phase of the SRR T2 program and was awarded a $1.5M prototype contract. Teal will develop a next-generation drone that meets or exceeds the Army's technical system requirements of SRR T2 and competes for the SRR T2 production contract.

08:12 EDT Liminal BioSciences provides update on lead drug candidate fezagepras - Liminal BioSciences provides an update on plans for the further development of its lead compound fezagepras. This announcement follows the completion of the company's analysis of the pharmacokinetic data from its Phase 1 MAD study of fezagepras in healthy volunteers. There were no significant drug related safety findings in the study. "Further to our announcement in 2021 that the company would not be progressing the development of fezagepras for the treatment of idiopathic pulmonary fibrosis nor hypertriglyceridemia, the PK data observed from the MAD study led us to conclude that, at this stage, any potential new indications to be evaluated in the development of fezagepras are not expected to be for the treatment of fibrosis", stated Dr. Jeffrey Smith, Liminal's Strategic Medical Advisor. Dr. Smith added, "The low plasma concentrations of fezagepras, combined with high level of metabolites, lead us to that conclusion. However, analysis of the metabolite data provided support for the hypothesis that fezagepras has nitrogen scavenging properties. This provides an opportunity for fezagepras' potential development in diseases associated with high plasma ammonia concentrations." "Based on our observations that fezagepras has demonstrated nitrogen scavenging capabilities, we intend to conduct further research, including a Phase 1a SAD clinical trial designed as a head-to-head comparison with sodium phenylbutyrate to provide comparative nitrogen scavenging data to support our development plan," stated Bruce Pritchard, CEO of Liminal BioSciences. "This will provide us with further data to determine if fezagepras is worth developing for one of the many potential indications where nitrogen scavenging is beneficial. We have initiated work to conduct the study and expect, subject to receiving the usual approvals, to commence the Phase 1a SAD clinical trial in the second quarter of 2022. We expect to have data in the third quarter of 2022 which will support whether or not to continue developing fezagepras as a nitrogen scavenger. We look forward to providing further updates on this potential opportunity as data becomes available." Subject to obtaining the required regulatory approvals, the company is planning on initiating a Phase 1a SAD, Randomized, open label, cross over, study to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose of fezagepras compared to Sodium Phenylbutyrate in Healthy Subjects.

08:11 EDT Kamada expands US leadership team with two appointments - Kamada (KMDA) announced the appointments of two executives to its U.S. leadership team. The Company appointed Jon Knight as Vice President, U.S. Commercial Operations, with responsibility for U.S. commercial activities related to its innovative medicines. Kamada also appointed Jonathan Ward as Director, Facilities and Construction, with responsibility for expanding plasma collection capacity by opening additional collection centers in the U.S. Knight has served in a variety of commercial leadership positions during a nearly 25-year career. Most recently, Knight was responsible for trade relations at TherapeuticsMD (TXMD). Ward brings more than 25 years of experience in facilities and construction management to Kamada. Most recently, Ward managed facility operations and maintenance for 54 plasma collection centers at Bio Products Laboratory.

08:10 EDT Fathom announces $10M share repurchase plan - Fathom Holdings announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $10M of its outstanding shares of common stock. The share repurchase authorization does not have a fixed expiration.

08:09 EDT Kaspien Holdings promotes Brock Kowalchuk to interim CEO - Kaspien Holdings (KSPN) announced that the company has promoted senior finance executive and organizational leader Brock Kowalchuk to the position of interim CEO, effective March 11. Kowalchuk joined Kaspien in September of 2018 as the Senior Vice President of Finance before being promoted a year later to CFO of Kaspien. Prior to Kaspien, Kowalchuk spent 7 years at Goldman Sachs (GS) in roles of increasing responsibility.

08:07 EDT Splash Beverage Group expands existing agreement with AB ONE - Splash Beverage Group (SBEV) announced the expansion of its existing agreement with AB ONE (BUD) to include AB ONE SoCal. Southern California is AB ONE's largest single market in the US and covers an area with a population of more than 20 million through national chains that include Walmart, Kroger, Albertsons and Winco Foods.

08:06 EDT Applied DNA in LOI with Spindle for LinearDNATM research collaboration - Applied DNA Sciences, and Spindle Biotech announced that the two companies have executed a non-binding letter of intent that outlines the terms of a collaborative research agreement to investigate the feasibility of utilizing the Company's LinearDNATM platform to produce chemically modified DNA templates for use in Spindle Biotech's proprietary, high yield RNA manufacturing system. The companies believe the combination of their respective platforms provides for a simplified, high yield, and 100% cell-free workflow that is differentiated from current mRNA production that uses plasmid DNA . In addition to increased speed and purity, the use of LinearDNA as an IVT template for mRNA production removes several complex manufacturing steps necessitated by pDNA. The companies believe that Spindle Biotech's proprietary, high yield, and engineered RNA polymerase, which requires a chemically modified DNA template, is particularly well suited to leverage the unique advantages of Applied DNA's PCR-based LinearDNA platform. Under the proposed Definitive Agreement terms, Applied DNA will produce specialized IVT DNA templates for RNA transcription using Spindle Biotech's RNA polymerase. Following initial validation work, the companies intend to explore the commercialization of an mRNA production system that leverages the benefits of the companies' respective platforms. Dr. James A. Hayward, president and CEO of Applied DNA, stated, "We believe that Spindle's mRNA manufacturing approach is a very good fit for our LinearDNA platform, which excels at the efficient production of chemically modified DNA constructs. As demand for mRNA therapeutics grows, Spindle Biotech and we are pursuing a simplified and efficient method to produce mRNAs with potential advantages in terms of cost, complexity, and production time versus standard pDNA methods to produce mRNA."

08:05 EDT Icahn Enterprises raises tender offer price for Southwest Gas to $82.50 - IEP Utility Holdings, an affiliate of Icahn Enterprises L.P., announced an increase in the purchase price to be paid in its cash tender offer for any and all of the issued and outstanding shares of the common stock of Southwest Gas Holdings, including the associated rights issued pursuant to the rights agreement, dated October 10, 2021, between the company and Equiniti Trust Company, as rights agent, that are issued and outstanding, to $82.50 per share in cash, without interest, less any applicable withholding taxes. The offer price of $82.50 per share represents a premium of 10% over the previous offer price of $75.00 per share and a premium of 27% over the closing price of $64.92 of the shares on October 13, 2021, the last trading day prior to the offeror's initial offer, Icahn noted.

08:04 EDT Phathom Pharmaceuticals submits Vonoprazan NDA to FDA for treatment of EE - Phathom Pharmaceuticals announced that it has submitted a new drug application to the U.S. Food and Drug Administration for the use of vonoprazan as a treatment for adults for the healing of all grades of erosive esophagitis and relief of heartburn, and maintenance of healing of all grades of EE and relief of heartburn. This NDA is based on the positive data previously announced from Phathom's pivotal Phase 3 PHALCON-EE trial, a randomized, double-blind, multicenter trial that enrolled 1,024 patients with EE in the U.S. and Europe and compared vonoprazan to lansoprazole, a standard of care PPI, in the healing and maintenance of healing of EE, and heartburn symptom relief. PHALCON-EE successfully met its primary endpoints and key secondary superiority endpoints.

08:04 EDT MingZhu Logistics enters share purchase agreement to acquire Yinhua - MingZhu Logistics announced it has entered into a Share Purchase Agreement to acquire Yinhua Limited, which develops and operates a comprehensive auto related service platform to serve auto insurance companies. MingZhu expects this acquisition to be immediately accretive to its revenue, gross margin and net income. The transaction is subject to closing conditions that are customary for transactions of this type. Under terms of the Share Purchase Agreement, MingZhu shall pay $18,302,500 in exchange for 100% equity of Yinhua. Of the total consideration to be paid, $15,304,000 shall be paid in form of 3,826,000 newly issued ordinary shares of MingZhu, representing $4.00 per ordinary share of MingZhu, and $1M cash upon closing. In addition, a cash earnout of $1,998,500 shall be paid if Yinhua achieves a net income target threshold of $1.3M during the calendar year 2022.

08:03 EDT Seer announces publication on technology platform for scalable proteomics - Seer announced the publication of a study demonstrating the performance of the technology platform underlying the Proteograph Product Suite for deep, unbiased, precise, scalable proteomics. The paper, entitled "Engineered Nanoparticles Enable Deep Proteomics Studies at Scale by Leveraging Tunable Nano-Bio Interactions," was published in The Proceedings of the National Academy of Sciences by an interdisciplinary team of scientists from Seer, Oregon Health Sciences University, Massachusetts Institute of Technology, and Harvard Medical School. The study examines in detail the relationship between the unique physicochemical properties of a panel of proprietary engineered nanoparticles and the diverse pattern of protein sampling that is enabled by a unique nano-bio interface that is created between a given NP surface and a given biological sample. The Seer machine learning model developed in this paper enhances understanding of the molecular interactions that occur at the nano-bio interface and shows how future NPs may be rationally designed using machine learning to differentially interrogate specific protein families. The proprietary nanoparticle technology described in the PNAS paper forms the foundation for Seer's Proteograph Product Suite, which is the only at scale solution available to deliver peptide and amino acid level resolution that enables identification of proteins and protein variants in an unbiased manner for deep, precise, and scalable proteomics studies. Understanding the proteome in health and disease, which is comprised of millions of protein variants, is believed to be key to unlocking biological insight to enable precision medicine. Deep, unbiased profiling of the plasma proteome at scale has not been possible with traditional workflows. In this study, Seer demonstrates superior performance of the technology platform underlying the Proteograph Product Suite. The technology platform simultaneously achieves an order of magnitude gain in median depth of coverage, 2x higher precision, 2.5x protein identifications and significant improvement in throughput in comparison to a conventional deep workflow. The performance of the Proteograph Product Suite uniquely enables population-scale unbiased studies where a large number of protein variants may be discovered. This performance is enabled by a panel of proprietary, engineered nanoparticles and this study demonstrates that the reproducible and quantitative dynamic range compression renders peptide and protein variant information significantly more accessible to downstream detectors independent of the LC-MS/MS acquisition mode. Using machine learning, the authors dissected the components of the physicochemical properties of proprietary engineered nanoparticles that contribute to the formation and composition of protein coronas. Correlations were identified between the physicochemical properties of nanoparticles and the abundance and functions of the specific proteins that interact with them. This structure-binding relationship will progressively enhance the ability to precisely and rationally design proprietary nanoparticles to orthogonally interrogate protein variants in different protein families, further enhancing the utility of nanoparticles in large-scale omics research and biomarker discovery.

08:02 EDT Yum China provides Q1 business performance update - Yum China Holdings updated its first quarter 2022 business performance in light of the recent COVID-19 development in China. "As we mentioned in the fourth quarter earnings release, same-store sales in January 2022 improved modestly from the fourth quarter, but were still down year over year, compared to the comparable Chinese New Year Holiday period in 2021. Entering March, the situation has rapidly deteriorated with the highly transmissible Omicron variant causing outbreaks across China, including economically important regions of Guangdong, Shanghai, Shandong and Jilin. Daily cases have hit a two-year high. Quarter-to-date case counts for 2022 have surpassed that of full year 2021. Stricter preventive health measures and containment measures have been observed nationwide, including multiple rounds of city-wide testing and partial or complete city lockdowns. Our operations are significantly impacted by the latest outbreaks and the tighter public health measures which resulted in a further reduction of social activities, travelling and consumption. Although the situation is still rapidly developing, we are providing the following first quarter 2022 update based on latest trends: Same-store sales: Decreased approximately 4% year over year for the two months combined in January and February. Decreased approximately 20% year over year for the first two weeks of March and is still trending down in recent days. Operating profit: Declined approximately 20% year over year for the two months combined in January and February, primarily due to the significant sales deleveraging and cost inflation. Based on the latest trend, we currently estimate that Operating profit for the first quarter to be in the range of $165 to $200 million. Stores temporarily closed or offered only takeaway and delivery services: Over 500 stores at the peak in January 2022. Over 1,100 stores as of March 13, 2022. Total store count reached 12,163 as of February 28, 2022, with 375 net new store openings for the two months combined in January and February."

07:58 EDT Sophia Genetics, REALM IDx sign LOI to collaborate on cancer research - Sophia Genetics and REALM IDx announced that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications. Together, the companies aim to expand next-generation sequencing research for cancer care and develop new multi-modal data streams to improve patient outcomes. The companies expect to enter into a definitive collaboration agreement following further discussion. As part of the intended collaboration, Sophia Genetics may use Ambry Genetics' lab for their sequencing needs. The companies believe that the combination of Ambry Genetics' decades of leadership in clinical next-generation sequencing and translational analysis and the SOPHiA DDM cloud-based analytics platform, can support improved clinical research decisions by pharmaceutical companies.

07:48 EDT Applied UV board approves one million share repurchase pact - Applied UV announces that its Board of Directors has authorized a common share repurchase program to repurchase up to one million shares 13.5% of the Company's public float of the Company's outstanding common stock. The share repurchase authorization is effective immediately and the Company's management team may make open market repurchases of the Company's common stock as authorized until September 30. Max Munn, Applied UV's interim CEO stated, "The Board's decision to authorize this share repurchase program reflects the Company's commitment to creating shareholder value, our strong balance sheet and the expectations we have for 2022."

07:45 EDT FTI Consulting appoints Randal Heeb as SMD in Economic Consulting segment - FTI Consulting announced the appointment of Dr. Randal Heeb as a Senior Managing Director in the firm's Economic Consulting segment. Based in Washington, D.C., Dr. Heeb has 35 years of experience providing economic analysis in both the private and public sectors. At FTI Consulting, Dr. Heeb will lead the Litigation and Dispute Resolution practice within the Economic Consulting segment, expanding FTI Consulting's capabilities in intellectual property and antitrust disputes, both in litigation and alternative dispute resolution settings. Dr. Heeb joins FTI Consulting from Bates White Economic Consulting, where he led the Intellectual Property practice and co-led the Antitrust and Competition practice.

07:42 EDT CareCloud promotes Steve Link to COO - CareCloud announced it has expanded its executive leadership team with several key promotions and strategic hires. The personnel moves are intended to support CareCloud's growth plans as the Company expands its market share and enhances its technology-enabled services to support its growing client base of more than 40,000 providers nationwide. Steve Link has been promoted to Chief Operating Officer, responsible for the Company's revenue cycle management operations and client success. Patti Peets has been promoted to Senior Vice President of Sales, responsible for the Company's sales operations, strategy, and expansion. As strategic hires, CareCloud has appointed Brian Zelenka as Vice President of Marketing, responsible for marketing strategy and demand generation, as well as Carinda "CJ" Cox as Vice President of Sales Operations, responsible for operational sales development and revenue growth goals. Link has been with CareCloud for nearly 10 years. As newly appointed Chief Operating Officer, Mr. Link manages the Company's continued growth and optimization of post-sales client service delivery which includes new account implementations, client support, client relationship management, and revenue cycle management operations. Patti Peets has been with CareCloud for eight years. As Senior Vice President of Sales, Ms. Peets leads the Company's sales efforts, focusing on growth and market expansion strategy and execution. Ms. Peets has 30 years of experience in sales, consulting, and healthcare IT. Prior to her new role, Ms. Peets was Vice President of Client Solutions as well as the Senior Director of RCM services for CareCloud, where she evaluated ambulatory clinics and hospitals revenue cycle to determine cost effective solutions based on ROI models. Carinda "CJ" Cox has been hired to support CareCloud's sales team as Vice President of Sales Operations. She works in lockstep with Brian Zelenka, CareCloud's new Vice President of Marketing, to achieve revenue growth goals and build the companies demand generation pipeline. In this role, Ms. Cox leads CareCloud's team of operational and sales development reps, delivers training, helps customers realize the benefits of technology-enabled services, and drives customer success, renewal, and retention. Ms. Cox has more than two decades of experience in healthcare technology and, prior to CareCloud, worked for Change Healthcare. Before joining CareCloud, Mr. Zelenka served in various leadership and consulting roles where he optimized marketing execution to increase revenue, improve productivity, and drive organic growth.

07:41 EDT Luna Innovations acquires LIOS Sensing for approximately $22M - Luna Innovations announced it has acquired LIOS Sensing , a division of NKT Photonics, a NKT A/S company for EUR 20M in cash. LIOS is a recognized market leader in distributed fiber optic monitoring solutions for power cable, pipelines, oilfield services, security, highways, railways and industrial fire detection systems. The acquisition will further expand Luna into these high-growth markets. "The acquisition of LIOS marks an important milestone for Luna. We are bringing together two complementary businesses which will further support our growth trajectory," said Scott Graeff, President and Chief Executive Officer of Luna. "Combining LIOS's market-leading position in temperature and strain sensing with Luna's broad fiber optic offerings, allows us to capitalize on significant technology advancements and enhanced market opportunities. We are very excited about welcoming LIOS to the Luna team." Luna is acquiring LIOS for EUR 20M, approximately $22M million in USD. The transaction was funded using a combination of Luna's cash position and its existing revolving line of credit. LIOS will become a fully owned subsidiary of Luna Innovations Incorporated, while continuing to operate under its existing brand for the foreseeable future. LIOS employees will remain within the company, with offices in Germany and the United States.

07:40 EDT Biogen announces updates across SMA Research Program - Biogen announced new data and updates from its SPINRAZA and spinal muscular atrophy research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies. These updates will be presented at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference. First Patient Treated in Phase 3b ASCEND Study The ASCEND study is currently enrolling with the first patient treated in Q1 2022. At the conference, Biogen will present the design of the open-label, global Phase 3b study to evaluate the potential benefit of investigational higher dose nusinersen in later-onset, non-ambulatory SMA patients previously treated with Evrysdi. The primary endpoint in ASCEND is the total change from baseline in the Revised Upper Limb Module score. The study will integrate smartphone-based digital assessments as an exploratory endpoint using Konectom NMD, a mobile application developed by Biogen Digital Health that will allow teen and adult participants to quantitatively and remotely self-assess motor function in their daily lives. Biogen Digital Health, a global unit of the company dedicated to pioneering personalized and digital medicine in neuroscience, will present more details about using digital outcome assessments within the core clinical development program to evaluate daily activities impacted by neuromuscular diseases. ASCEND aims to enroll approximately 135 children, teens and adults previously treated with Evrysdi. All participants will receive higher dose nusinersen in the study. Information on the ASCEND study is available at clinicaltrials.gov. Ongoing Research Aims to Inform SMA Treatment Decisions Biogen will also present baseline characteristics from the RESPOND study investigating the efficacy and safety of SPINRAZA in infants and toddlers who still have unmet clinical needs following treatment with Zolgensma. All study participants who previously received the gene therapy showed suboptimal clinical status in two or more domains at baseline, the most common being motor and respiratory function. Initial safety findings indicate none of the adverse events or serious AEs reported were considered related to SPINRAZA treatment. Additionally, the latest results from NURTURE, a study in infants treated in the presymptomatic stage of SMA, demonstrate that early and sustained treatment with SPINRAZA for up to 5.7 years helped participants to maintain and make progressive gains in motor function. After 11 months of additional follow-up since the 2020 interim analysis, all children who were able to walk alone maintained this ability and one child gained the ability to walk alone, increasing the total percentage to 92 percent. Most children achieved motor milestones within age-appropriate timelines1 and no major motor milestones were lost. The safety of SPINRAZA over this extended follow-up period was consistent with previously reported findings.

07:38 EDT DocGo appoints Lee Bienstock as COO - DocGo (DCGO) announced the hiring of Lee Bienstock as the company's new COO. Bienstock joins DocGo after ten years at Google (GOOG), where he held leadership roles, which included the launching of Google Fiber, driving early growth in Google's Search and YouTube advertising businesses, and most recently developing and executing strategic initiatives for Google's growing suite of connected devices.

07:35 EDT Novartis reports data from Phase 3 SPR1NT study - Novartis announced new data that it said "reinforce the transformational benefit of Zolgensma," an essential one-time treatment for spinal muscular atrophy, or SMA. The completed Phase 3 SPR1NT study demonstrated that children with three copies of the SMN2 back-up gene who were treated presymptomatically achieved age-appropriate motor milestones, including standing and walking. In addition, a descriptive post-hoc analyses of START, STR1VE-EU and STR1VE-US indicated children with SMA Type 1 achieved or maintained important measures of bulbar function following treatment with Zolgensma, including ability to speak; swallow and meet nutritional needs; and maintain airway protection. These data are among a Zolgensma data set being presented during the 2022 Muscular Dystrophy Association Clinical and Scientific Conference, which also include, in part, real-world data from the RESTORE registry and a chart review of US patients who changed therapy to Zolgensma. Without treatment, most children with three copies of the SMN2 back-up gene develop SMA Type 2, characterized by the inability to walk independently. In contrast, 14/15 children in the three-copy cohort of SPR1NT went on to walk independently, most, or 11/15, within the World Health Organization window of normal development. All 15 children met the primary endpoint of standing alone greater than or equal to 3 seconds, including 14/15 within the WHO window of normal development. All children were free of feeding tube support and ventilatory support of any kind during the study, and no serious, treatment-related adverse events were reported, the company reported.

07:34 EDT Paratek Pharmaceuticals sees cash runwaythrough the end of 2023 - Based upon the company's current operating plan, Paratek anticipates its existing cash and cash equivalents of $95.5 million as of December 31, 2021, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.

07:32 EDT Paratek to increase U.S. sales reps in primary care setting in 2022 - The company said, "Based on the continued success and progress of the company's NUZYRA community expansion, Paratek plans to increase the number of U.S. sales representatives and territories covered in the primary care setting in 2022. The company expects to execute this expansion within its previously communicated cash runway guidance."

07:32 EDT Turquoise Hill confirms receipt of privatization proposal from Rio Tinto - Turquoise Hill Resources (TRQ) acknowledged receipt of a non-binding proposal from Rio Tinto (RIO), which Rio Tinto has separately announced by press release issued earlier, outlining its proposal to acquire the approximately 49% of the outstanding shares of Turquoise Hill held by the company's minority shareholders for cash consideration of C$34.00 per share. Rio Tinto has stated that its proposal is conditional on, among other things, Turquoise Hill not raising additional equity capital, including through a rights offering, bought deal or other share placement, pending completion of the proposed transaction. The Rio Tinto proposal does not amend the terms of the amended and restated Heads of Agreement entered into by Turquoise Hill and Rio Tinto on January 24, which establishes a binding funding plan for the completion of the Oyu Tolgoi underground mine. The board of directors of the company will be establishing a special committee of independent directors to review and consider Rio Tinto's proposal. Turquoise Hill shareholders do not need to take any action with respect to the proposal at this time.

07:27 EDT Ameresco partners with YDMT to plant 500 trees - Ameresco announced that it has partnered with Yorkshire Dales Millennium Trust, or YDMT, an independent charity dedicated to the preservation of woodlands in the Yorkshire Dales, to plant 500 trees across the region this year.

07:21 EDT Clene presents updated clinical data from Phase 2 RESCUE-ALS, REPAIR trials - Clene announced multiple presentations of updated clinical trial results from the Phase 2 RESCUE-ALS and REPAIR trials in addition to new mechanistic preclinical data in ALS at the 2022 MDA Clinical & Scientific Conference, taking place March 13-16 in Nashville. The first poster, titled "RESCUE-ALS Trial Results: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS," selected as an oral presentation, and the second poster, "Evidence for a Potential Survival Benefit with CNM-Au8 Treatment from the RESCUE-ALS Trial Long-Term Open Label Extension," further support Clene's lead drug candidate CNM-Au8, a catalytically active gold nanocrystal suspension, as a potential disease-modifying therapy for amyotrophic lateral sclerosis, ALS. RESCUE-ALS, a Phase 2 trial examined the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in 45 participants with early ALS over a 36-week treatment period. In the 36-week blinded period, there were significant benefits with CNM-Au8 treatment: slowing ALS disease progression, decreasing the proportion of participants with a 6-point decline in the ALS Functional Rating Scale Revised, and improving quality of life as measured by the ALS Specific Quality of Life questionnaire. The second poster presented updated evidence for survival benefit with CNM-Au8 treatment that was reported from the RESCUE-ALS trial long-term open label extension for both the active and placebo groups. Interim analyses of observed survival compared to estimated median survival derived from the validated ENCALS prediction model significantly favored CNM-Au8 treatment with a hazard ratio of 0.3 for participants who entered the open-label extension. CNM-Au8 was shown to be well-tolerated with no safety signals identified over 96 weeks of treatment. The third poster, titled "Evidence for Brain Energy Metabolic Support with CNM-Au8 Treatment: Results from Phase 2 REPAIR Clinical Trial With CNM-Au8," demonstrated improved brain energy metabolism assessed by high-resolution magnetic resonance spectroscopy. CNM-Au8 treatment resulted in improved brain NAD+/NADH ratio. This result was driven both by increase in NAD+ and a decrease in NADH. The fourth poster accepted for presentation, "CNM-Au8 Gold Nanocatalysis Protects Neurons Against Degeneration and Death in Multiple in vitro models of ALS," demonstrates CNM-Au8's ability to promote neuronal survival and function in multiple independent in vitro models of ALS: treatment of primary rat spinal motor neurons improved survival, preserves the neurite networks, and reduced cytoplasmic TDP-43 aggregate accumulation; treatment of spinal motor neurons from transgenic SOD1G93A rats protected motor neurons from death upon exposure to excitotoxic glutamate in a cAMP-dependent manner, and reduced SOD1 protein accumulation in a manner independent of cAMP; treatment of human induced pluripotent stem cell-derived neurons from C9ORF72 patients prevented neuronal death in response to stressors; and survival and neurite outgrowth of human iPSC-derived motor neurons in co-culture with toxic SOD1A4V ALS-patient derived astrocytes were significantly and dose-dependently improved with treatment of CNM-Au8.

07:17 EDT Myriad Genetics launches Precise Oncology Solutions offering - Myriad Genetics announced the launch of Precise Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treatment plans for individual patients. The new suite provides physicians with streamlined testing that combines germline testing, tumor profiling and companion diagnostic options including evaluation for Homologous Recombination Deficiency, an important cancer repair pathway. Precise Oncology Solutions includes Myriad's new Precise Tumor Molecular Profile Test, developed in collaboration with Intermountain Precision Genomics, leading healthcare providers, and industry partners. In pairing the tumor test with Myriad's MyRisk Hereditary Cancer Test and its two companion diagnostic tests, MyChoice CDx and BRACAnalysis CDx, Myriad offers a testing combination that provides integrated genetic insights and makes it easier to tailor therapy and clinical trial selection. Precise Oncology Solutions is currently available for patients with solid cancer tumors. Precise Oncology Solutions includes Myriad's two companion diagnostic tests. MyChoice CDx, which is FDA approved for patients with ovarian cancer, examines ovarian cancer tumors using BRCA1/2 mutation and genomic instability to determine a patient's HRD status and resulting eligibility for targeted therapy. BRACAnalysis CDx identifies patients with a germline BRCA1/2 mutation and helps identify targeted treatment recommendations for patients with breast, ovarian, pancreatic and prostate cancers. As part of this offering, healthcare providers can now place a single order for multiple Myriad tests and receive timely results through a new unified online portal. Myriad is also introducing a new Precise Treatment Registry that combines germline, somatic and HRD genetic data with patient outcomes to accelerate the pace of precision cancer research and equitable advancements in patient care. The registry is powered by DNAnexus' secure, cloud bioinformatics platform for scientific data analysis, collaboration and discovery. The registry will enable clinicians to explore hypotheses in real-time by analyzing diverse de-identified patient data involving ancestry, geography, cancer diagnosis, treatment outcomes, and more. Over the next few years, Myriad plans to further expand its oncology portfolio into liquid biopsy applications, including Minimal Residual Disease detection. These offerings will be based on the company's scientific platforms and capabilities as well as potential industry partnerships with other healthcare innovators.

07:16 EDT Lantern Pharma to present 'positive' data on LP-184 at AACR meeting - Lantern Pharma announced that it will present positive preclinical data on the in vitro efficacy of its drug candidate LP-184 in brain metastases at the American Association of Cancer Research annual meeting, April 8-13th, held in New Orleans, Louisiana. The virtual poster will be presented by Lantern Pharma in collaboration with Johns Hopkins School of Medicine and the Kennedy Krieger Institute and will describe positive preclinical data demonstrating the effectiveness of LP-184 treatment in brain mets cell models derived from patient lung, skin, and breast cancers. The poster will also show that in an in vitro model of brain mets from lung cancer, LP-184 treatment was found to be 6 times more potent than EGFR tyrosine kinase inhibitors.

07:14 EDT Travelzoo creates new Metaverse division - Travelzoo announces the creation of its new Metaverse division and the plan to begin the launch of its Travelzoo META service in April. Travelzoo META is a paid subscription-based service that provides members with exclusive access to the latest and best Metaverse travel experiences. Since January, Travelzoo has been building a team of Metaverse travel experience scouts in collaboration with a partner. While Travelzoo will not produce Metaverse destinations and experiences itself, it will work with hundreds of creators to make experiences exclusively available to Travelzoo META members. The build-up of the new business is expected to be funded from annual membership fees to be paid by Travelzoo META members.

07:13 EDT Natera says executives, board to take pay in stock instead of cash for 2022 - Natera announced that its executive leaders and board of directors have unanimously agreed on a compensation change that will see them take company stock instead of their salaries and retainers for the remainder of 2022.

07:12 EDT New York MTA selects Atlas, WSP to provide oversight on Penn Station project - Atlas Technical Consultants announced that it was selected, as part of a Joint Venture with WSP USA, to provide project management services for the Penn Station Access Project. The $115m contract was awarded by the Metropolitan Transportation Authority to the JV team, for construction management, design oversight, operations management, and commercial management. The contract term is for 86 months, which includes a 12-month option for additional services. The project will deliver a new transit option providing direct Metro-North service from the Bronx, Westchester, and Connecticut to Penn Station and Manhattan's west side.

07:11 EDT GoldMining acquires existing NSR royalty on Yarumalito Project, Colombia - GoldMining is pleased to announce that it has acquired an existing 1% net smelter return royalty on the company's Yarumalito Project in Colombia from Newrange Gold Corp. Pursuant to the agreement, the company paid Newrange C$100,000 in cash and delivered 10,000 common shares of the company.

07:10 EDT Silver Bull announces resignation of director Jack McClintock - Silver Bull Resources (SVBL) wishes to announce changes to its Board of Directors. Effective March 3, 2022, Jack McClintock has resigned from the Board of Directors for personal reasons. Mr. McClintock has been a member of the Board since 2012. To replace Mr. McClintock, Mr. David Underwood has been appointed to the Board. Since January 2017, Underwood has been the Vice President of Exploration of Osino Resources (OSIIF) in Namibia. Mr. Underwood is also a co-founder of, and since June 2020 has been a technical advisor for, Lotus Gold, a private company focused in Egypt. The company also announces the grant of 3,300,000 stock options that are exercisable for a period of five years at a price of C$0.32 per share to various directors, officers, employees and consultants. The options will be subject to vesting over two years. The granting of stock options is part of Silver Bull's strategy to attract and retain talent, as well as motivating its team to work toward ensuring the success and value creation at Silver Bull.

07:09 EDT Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer - Elevation Oncology (ELEV) announced the appointment of David Dornan, Ph.D. as the company's Chief Scientific Officer. Dr. Dornan joins Elevation Oncology from Bolt Biotherapeutics (BOLT).

07:08 EDT Hexo announces High Trail waives event of default under secured note - HEXO Corp. (HEXO) is pleased to announce today that HT Investments MA, the holder of the Company's senior secured convertible note due May 2023, has irrevocably waived any rights in relation to the breach of the covenant of the Company in the Secured Note to have positive Adjusted EBITDA as defined and calculated in the Secured Note for the three-month period ending on January 31, 2022. HEXO provided notice on March 11, 2022 to the Noteholder of the occurrence of an event of default under the Secured Note since it was not in compliance with the covenant of the Company in the Secured Note to have positive Adjusted EBITDA as defined and calculated in the Secured Note for the three-month period ending on January 31, 2022. The Noteholder has irrevocably waived their rights due to the Event of Default until the earlier of May 17, 2022 or the date the proposed transaction announced on March 3, 2022 among the Company, the Noteholder and Tilray Brands (TLRY) under which Tilray is expected to purchase the Secured Note from the Noteholder is terminated, provided further that the Company, the Noteholder and Tilray have agreed to extend the End of Forbearance Date in the event that they remain engaged in good faith negotiations to consummate the proposed transaction. As a result of the Event of Default, the Noteholder would have had the right to declare the Secured Note or any portion of it to become due and payable immediately for cash in an amount equal to 115% of the outstanding principal amount of the Secured Note. The current outstanding principal amount of the Secured Note, which was issued with an initial principal amount of $360,000,000 but which has been reduced through redemptions by the Noteholder, is $208,665,185.

07:07 EDT Glaukos commences iLink therapy clinical program - Glaukos announced that it has commenced a Phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos' iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce a reaction called corneal cross-linking designed to strengthen, stabilize and reshape the cornea. Glaukos' third-generation iLink therapy is a corneal cross-linking treatment designed to customize the therapeutic capabilities, streamline the patient experience and build upon Glaukos' first-generation iLink therapy, known as iLink Epi-off, and its second-generation iLink investigational therapy, known as iLink Epi-on.

07:06 EDT Aveo Pharmaceuticals expects cash to fund operations for more than 12 months - AVEO believes that its $87.3M in cash, cash equivalents and marketable securities as of December 31, 2021, along with expected net product revenues from the sales of FOTIVDA in the United States, will enable AVEO to maintain its current operations for a period of more than 12 months from the date of filing of its Annual Report on Form 10-K for the year ended December 31, 2021.

07:03 EDT Apyx Medical notified of pending Medical Device Safety Communication from FDA - Apyx Medical announced it has been notified by the FDA that the agency intends to post a Medical Device Safety Communication related to the company's Advanced Energy products. "Based on our initial interactions with the FDA, we believe the Agency's MDSC will pertain to the use of our Advanced Energy products outside of their FDA-cleared indication for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures," said Charlie Goodwin, president and Chief Executive Officer. "We support the FDA's focus on ensuring that healthcare providers and patients understand the safe and proper use of our products, as we continue to work towards securing 510(k) clearance for additional indications."

07:02 EDT Tonix Pharmaceuticals expects to initiate several clinical trials in 2022 - Gregory Sullivan, M.D., Chief Medical Officer of Tonix said, "In 2022, we expect to initiate several clinical trials. We intend to start a Phase 1 study of TNX-1500, a humanized monoclonal antibody with several potential indications including the prevention of organ transplant rejection and treatment of autoimmune disorders. Within our CNS pipeline, we expect to start a Phase 2 study of FDA Breakthrough Therapy-designated product candidate TNX-1300 for cocaine intoxication in the emergency room setting. We also expect to start three trials for TNX-102 SL including: a confirmatory Phase 3 study for the management of fibromyalgia, a Phase 2 study for the treatment of PTSD, and a Phase 2 study for the treatment of Long Covid. Finally, in 2022 we intend to start a Phase 2 study of TNX-1900 for the treatment of migraine and an investigator-initiated Phase 2 study of TNX-1900 for binge eating disorder."

06:58 EDT TreeHouse provides update on strategic review of alternatives - TreeHouse provided an update on the evaluation of strategic alternatives. After discussion and deliberation, and with input from independent legal and financial advisors, the board has concluded that the focus of its ongoing strategic review will be to continue reshaping TreeHouse by building leadership and depth around a focused group of categories in its higher-growth snacking and beverages business. TreeHouse will continue its exploration of potential divestiture transactions, including the sale of portions of the meal preparation business, either in a single transaction or in a series of transactions. The board also has unanimously determined it is not the right time to pursue a sale of the whole company, but it remains open to all alternatives to maximize shareholder value.

06:46 EDT Ecolab announces intent to repurchase $500M of shares - Ecolab announced its intent to repurchase $500M of its shares in 2022. Ecolab had approximately 286M shares outstanding on February 28, 2022. The repurchases are pursuant to the previously announced February 2015 share repurchase authorization by Ecolab's Board of Directors. No further details regarding the repurchase program were announced.

06:42 EDT AstraZeneca says FDA issued complete response letter for Fasenra sBLA - The U.S. Food and Drug Administration has issued a complete response letter, or CRL, regarding the supplemental Biologics License Application, or sBLA, for Fasenra for patients with inadequately controlled chronic rhinosinusitis with nasal polyps, or CRSwNP, AstraZeneca announced. "The sBLA submitted to the FDA by AstraZeneca included data from the OSTRO Phase III trial, which met both co-primary endpoints with a safety profile consistent with the known profile of the medicine. The CRL requested additional clinical data and the company is working closely with the FDA regarding next steps. The company remains committed to bringing Fasenra to patients with CRSwNP and a second Phase III trial, ORCHID, in this indication is ongoing. Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma in the US, EU, Japan and other countries and is approved for self-administration in the US, EU and other countries," the company stated.

06:36 EDT AZZ Inc. awarded contract to provide 125 BESS enclosures - AZZ Inc. announced a contract award to provide 125 Battery Energy Storage System, or BESS, enclosures for one of the largest energy storage facilities in North America. The total value of the contract was not disclosed. Delivery of the lithium-ion BESS enclosures is scheduled to begin the second half of 2022 with project completion anticipated in June 2023.

06:33 EDT BitNile launches new division for blockchain, cryptocurrency mining solutions - BitNile Holdings announced that its subsidiary, BitNile, Inc. has formed a new division, BitNile Mining Solutions. BitNile's cryptocurrency mining focus to date has been on self-mining Bitcoin. BMS will leverage BitNile's deep industry partnerships, including its partnership with Bitmain Technologies Limited. BMS will focus on the sourcing and sales of cryptocurrency miners and related equipment and offering additional blockchain infrastructure services such as hosting, managing electrical power, repair and other crypto-focused infrastructure solutions. BMS will offer products and services to companies ranging from start-ups to providing fully integrated industrial operations and solutions including self-mining. Interested parties can contact the new division at Solutions@BitNile.com.

06:21 EDT Ford moves to electric future in Europe, seven new EV, EV production in Cologne - Ford announced strides toward an all-electric future in Europe, which will see the company transformed and offering a new generation of seven, all-electric, fully-connected passenger vehicles and vans by 2024. With its extended range of electric passenger and commercial vehicle models, Ford expects its annual sales of electric vehicles, EVs, in Europe to exceed 600,000 units in 2026, and also reaffirmed its intention to deliver a 6% EBIT margin in Europe in 2023. The acceleration in Europe supports Ford's goal to sell more than 2M EVs globally by 2026 and deliver company adjusted EBIT margin of 10%. The company announced it is targeting zero emissions for all vehicle sales in Europe and carbon neutrality across its European footprint of facilities, logistics and suppliers by 2035. Seven new electric vehicles by 2024: Ford unveiled plans for seven all-electric vehicles to join the Ford family in Europe - three new passenger vehicles and four new commercial vehicles. Starting in 2023, Ford will begin production of an all-new electric passenger vehicle, a medium-sized crossover, built in Cologne with a second electric vehicle added to the Cologne production line-up in 2024. In addition, Ford's top-selling passenger vehicle in Europe, the Ford Puma, will be available as an electric version made in Craiova, Romania, starting in 2024. EV production and investment in Cologne: Ford confirmed that the first volume all-electric passenger vehicle to come out of the Ford Cologne Electrification Centre will be a five-seat, medium-sized crossover. Capable of a 500km driving range on a single charge, the vehicle and its name will be revealed later in 2022, with production commencing in 2023.

06:09 EDT Velodyne Lidar announces board change, update on stock ownership - Velodyne Lidar announced that Eric Singer, a Velodyne Board member, has retired from the company's Board of Directors, effective March 13. Singer was previously elected to the Board at the 2021 Annual Meeting of Stockholders following his nomination by David Hall. In conjunction with his departure from the Board of Directors, the company and Eric Singer have reached a cooperation agreement. Under the agreement, Mr. Singer, a tech veteran with experience in corporate governance, strategic planning and shareholder relations, will serve as a consultant to the company and will help identify an independent director to fill the vacancy on the Board left due to his retirement. The company also confirmed receipt of Hall's notice of nomination of three candidates, including David Hall and Marta Thoma Hall, to stand for election to the Velodyne Board of Directors at the company's 2022 Annual Meeting of Stockholders. As he has reported with the SEC, Hall recently sold 45.8M shares of Velodyne stock publicly - the maximum allowed under Rule 144 of the Securities Act of 1933, as amended. Taken together with his cancellation of certain of his Proxy and Lock-Up Agreements of shares held by other stockholders, Hall and Ms. Hall have significantly reduced their beneficial ownership and voting positions, only further demonstrating their fundamental misalignment with the interests of all Velodyne shareholders. The company notes that Hall sold his shares in the course of only seven trading days, which the company believes had a significant short-term negative impact on the price of the company's stock.

06:04 EDT KBR to update 2025 financial guidance to reflect HomeSafe Alliance JV - KBR will provide an update to its 2025 long-term financial targets to reflect the anticipated financial benefits of its HomeSafe Alliance joint venture with Tier One Relocation. KBR has a 72% ownership interest in HomeSafe, which was awarded the global household goods contract by U.S. Transportation Command in November 2021. HomeSafe will be the exclusive move manager for approximately 325,000 global moves annually. The contract has a ceiling value of $20B and is expected to provide KBR with strong earnings and cash accretion, increased funding source diversification, and enhanced long-range visibility. "We are very pleased to bring a technology-enabled, end-to-end solution to improve the relocation experience for our brave service members and their families," said Stuart Bradie, KBR President and CEO. "HomeSafe Alliance is an on-strategy win for KBR, and our team of teams is excited and ready to transform the military move program with a disruptive, digitally-enabled, sustainable solution. KBR delivered a terrific year in 2021, and the global household goods contract award and updated 2025 outlook reflect the continued momentum in our business and significant value creation opportunities for our shareholders."

05:32 EDT W&T Offshore promotes William Williford to COO - W&T Offshore announced the promotion of William Williford to executive VP and COO. Williford joined W&T in June 2006 and most recently served as executive VP and GM Gulf of Mexico.

05:13 EDT Rio Tinto makes proposal to fully acquire Turquoise Hill for C$34 per share - Rio Tinto (RIO) has made a non-binding proposal to the Turquoise Hill (TRQ) board to acquire the approximately 49% of the issued and outstanding shares of Turquoise Hill that Rio Tinto does not currently own. Under the terms of the proposed transaction, Turquoise Hill minority shareholders would receive C$34 in cash per Turquoise Hill share, representing a premium of 32% to Turquoise Hill's last closing share price on the Toronto Stock Exchange. This proposal would value the Turquoise Hill minority share capital at approximately $2.7B. The proposed transaction follows the recent agreement reached between Rio Tinto, Turquoise Hill and the Government of Mongolia to move the Oyu Tolgoi project forward, reset the relationship between the partners and approve commencement of underground operations. Rio Tinto's proposal to the Turquoise Hill board will be filed promptly with the Securities and Exchange Commission in accordance with applicable laws and regulations in the United States. The proposed transaction, which is expected to be conducted by way of a Canadian plan of arrangement, will be subject to customary closing conditions, including approval by a majority of the votes cast by Turquoise Hill minority shareholders. The proposed transaction is not subject to any financing condition or due diligence. No agreement has been reached between Rio Tinto and Turquoise Hill, and there can be no assurance that any transaction will result from these discussions. Even if a transaction is agreed, there can be no assurances as to its terms, structure or timing.

05:06 EDT Li Auto announces inclusion of shares in Shenzhen-Hong Kong Stock Connect - Li Auto announced that the company's Class A ordinary shares, which are listed and traded on the Stock Exchange of Hong Kong Limited, or HKEX, have been included in the Shenzhen-Hong Kong Stock Connect program, effective immediately, based on the announcement of the Shenzhen Stock Exchange. The inclusion in the Shenzhen-Hong Kong Stock Connect program allows the company to access a broader investor base and share its growth trajectory and further success with users, partners and investors in mainland China via the financial market.

04:55 EST BellRing Brands to replace Cerence in S&P 400 at open on 3/14 - Post Holdings (POST) is converting its interest in BellRing Brands (BRBR) into new BellRing Brands stock and then distributing 80.1% of that interest to shareholders on March 11. Following the distribution, Post Holdings will remain in the S&P MidCap 400. Immediately prior to the transaction, BellRing Brands will consolidate its multiple share class structure into a new single share class structure. Post transactions, BellRing Brands' market capitalization will be more representative of the mid-cap market space.